What Is the Value of a Human Life and How Many Lives Could NASA’s Budget Save?

As an Amazon Associate we earn from qualifying purchases.

Key Takeaways

• Federal agencies value a statistical human life between $13.6 million and $14.2 million for regulatory analyses.
• Heart disease, cancer, and unintentional injuries caused 48.8% of the 3,072,666 United States deaths in 2024.
• Redirecting NASA’s $24.4 billion budget could save thousands of domestic lives or millions of lives globally.

How Economists and Federal Agencies Calculate the Value of a Human Life

On October 20, 2026, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) within the United States Department of Health and Human Services (HHS) published updated economic modeling establishing the central value of a human life for statistical risk reduction at $14.1 million for the year 2026. Across the federal government, regulatory economists apply this figure, formally termed the Value of a Statistical Life (VSL), whenever an executive agency evaluates a highway barrier specification, an ambient air pollution threshold, a clinical organ procurement reform, a commercial aviation safety mandate, or a consumer product recall. Assigning a dollar benchmark to the value of a human life in public policy does not involve appraising the intrinsic moral worth, personal dignity, or legal standing of an identified human being. Rather, the metric aggregates the dollar amount that a large population of citizens is willing to pay for small reductions in premature mortality probabilities such that one fewer death is expected across that population over a single year.

From Human Capital Accounting to Willingness to Pay

Prior to the late 1960s, government budget offices and civil courts evaluated premature mortality primarily through the human capital approach. Under human capital accounting, actuaries and economists calculated the discounted present value of an individual’s expected future labor market earnings and household production, sometimes subtracting personal consumption expenditures to measure net economic contribution to society. Although simple to compute from census wage tables, human capital valuation generated severe policy distortions whenever public agencies evaluated health and safety regulations. Because foregone earnings tied the monetary benefit of survival directly to future paychecks, the formula assigned a negligible or even negative monetary weight to retired older adults, chronically ill patients, severely disabled children, and low-wage workers. If a public health department relied on human capital accounting to evaluate a clean air rule preventing cardiopulmonary deaths among octogenarians or a nutritional program protecting low-income infants, the resulting benefit-cost ratio systematically favored inaction.

The intellectual shift toward modern risk valuation began in 1968 when economist Thomas Schelling published his foundational essay on the life you save, establishing a rigorous analytical distinction between an identified life and a statistical life. When a specific, named individual is trapped in a collapsed mine shaft, lost at sea, or stranded aboard a damaged spacecraft, democratic societies routinely mobilize tens of millions of dollars in emergency rescue assets without conducting a benefit-cost calculation. Public health budgets and regulatory standards operate before the fact across millions of anonymous residents whose individual identities cannot be known in advance. Schelling observed that ordinary citizens constantly make personal, voluntary tradeoffs between financial resources and small changes in mortality hazards, whether by paying more for vehicles equipped with advanced braking systems, purchasing smoke alarms and bicycle helmets, or demanding higher hourly wages to accept dangerous occupational duties.

Building upon Schelling’s theoretical framework during the 1970s and 1980s, economist W. Kip Viscusi pioneered empirical hedonic wage-risk econometrics. By linking household and establishment survey data on worker compensation with industry-specific and occupation-specific fatality rates compiled by the Bureau of Labor Statistics (BLS) Census of Fatal Occupational Injuries (CFOI), labor economists isolated the compensating wage differential that workers require to accept an elevated probability of fatal workplace injury. As the Environmental Protection Agency (EPA) illustrates in its mortality risk valuation guidance, if 100,000 individuals are each willing to pay $141 per year, or forego $141 in annual wages, to reduce their personal probability of dying during the next year by one in 100,000 (0.001%), the collective willingness to pay across that group equals $141 multiplied by 100,000, or $14.1 million. Because reducing fatal risk by one in 100,000 across 100,000 people yields an expected reduction of exactly one statistical death, the Value of a Statistical Life equals $14.1 million.

Federal institutionalization of the willingness-to-pay VSL framework began under Presidential Executive Order 12291 in 1981 and achieved permanent bipartisan codification under Executive Order 12866 in 1993 alongside Office of Management and Budget (OMB) Circular A-4. Under these executive mandates, federal agencies must conduct a formal Regulatory Impact Analysis (RIA) for all major rulemakings before publication in the Federal Register. Within each RIA, agency economists quantify expected physical health and safety outcomes, multiply prevented statistical fatalities by the agency’s official VSL benchmark, and compare the resulting monetized benefits against the compliance costs imposed on private industry, state and local governments, and consumers.

Econometric Mechanics of Hedonic Wage and Stated Preference Models

Deriving a defensible value of a human life from labor market data requires resolving complex econometric challenges. In a standard hedonic wage regression, an analyst models the natural logarithm of a worker’s hourly wage as a function of human capital variables (educational attainment, years of work experience, tenure with the current employer, union representation, occupation category, marital status, geographic region, and urban residency), non-monetary job characteristics (physical demands, shift work, non-fatal injury and illness rates), and the annual fatal occupational injury rate per 100,000 full-time-equivalent workers. The regression coefficient on the fatal injury rate measures the marginal slope of the market wage-offer curve with respect to mortality risk.

Early cross-sectional wage-risk studies published during the 1970s and 1980s relied on broad one-digit or two-digit industry fatality averages from the National Institute for Occupational Safety and Health or the BLS annual survey. Because industry-wide averages assigned the same fatality risk to a corporate accountant and a structural ironworker employed within the same construction sector, measurement error and unobserved worker heterogeneity produced wide variations in published VSL estimates, ranging from under $1.0 million to nearly $30.0 million. Two methodological advances resolved much of this dispersion. First, the creation of the BLS Census of Fatal Occupational Injuries in 1992, which cross-verifies every workplace fatality in the United States using death certificates, workers’ compensation reports, Occupational Safety and Health Administration (OSHA) inspection files, and medical examiner records, enabled researchers to construct multi-year cell averages stratified simultaneously by detailed industry and occupation. Second, econometricians led by Thomas J. Kniesner, W. Kip Viscusi, Christopher Woock, and James P. Ziliak applied longitudinal panel data estimators, such as first-difference and fixed-effects regressions using the Panel Study of Income Dynamics (PSID), to control for latent individual differences in safety productivity, risk preferences, and cognitive skills. As demonstrated in their panel data econometrics research, controlling for latent worker heterogeneity, state dependence, and measurement error narrows the econometrically valid VSL in the United States to a tight band that, once updated for consumer price inflation and real wage growth, aligns directly with the $13.6 million to $14.2 million benchmarks used by federal agencies in 2026.

To complement revealed-preference labor market studies, federal economists also draw upon stated-preference research, including contingent valuation surveys and discrete choice experiments. Stated-preference studies are essential when agencies evaluate mortality hazards that differ structurally from acute workplace trauma, such as latent cancers caused by drinking-water contaminants, pediatric product hazards affecting infants who do not participate in the labor force, or chronic respiratory mortality among retired populations. In 2025, the Organization for Economic Co-operation and Development (OECD) completed an international meta-analysis examining 277 mortality valuation studies across 49 countries published between 1970 and 2023, including 30 newer United States studies conducted between 2009 and 2023, confirming that rigorous stated-preference and revealed-preference protocols converge on robust positive valuations for micro-risk reductions.

Current Federal Agency Valuation Benchmarks in 2026

Although OMB Circular A-4 provides government-wide analytical principles, each cabinet department and independent regulatory commission maintains its own VSL series calibrated to specific base-year literature reviews and annual adjustment formulas. As of October 28, 2026, the primary United States regulatory agencies apply the following official mortality valuation benchmarks:

The United States Department of Transportation (DOT) publishes the most explicit annual VSL series in the federal government. Under its Departmental Guidance on Valuation of a Statistical Life in Economic Analysis, carrying an effective date of March 20, 2026, the Office of the Secretary of Transportation sets the official VSL at $14.2 million for analyses using a 2025 base year. The DOT series originates from a 2013 synthesis of nine BLS CFOI hedonic wage studies that established a $9.1 million benchmark for base year 2012. Each year, the DOT Office of the Chief Economist adjusts that base figure using the Consumer Price Index for All Urban Consumers (CPI-U) and the change in real median weekly earnings from the BLS Current Population Survey, applying an income elasticity of 1.0 (meaning a 1% increase in real income raises willingness to pay for safety by 1%). Through this formula, the DOT VSL rose from $9.1 million in 2012 to $9.2 million in 2013, $9.4 million in 2014, $9.6 million in 2015, $9.9 million in 2016, $10.2 million in 2017, $10.5 million in 2018, $10.9 million in 2019, $11.6 million in 2020, $11.8 million in 2021, $12.5 million in 2022, $13.2 million in 2023, $13.7 million in 2024, and $14.2 million for the 2025 base year governing 2026 analyses. Every operating administration within the department, including the Federal Highway Administration (FHWA), the National Highway Traffic Safety Administration (NHTSA), the Federal Aviation Administration (FAA), the Federal Railroad Administration (FRA), and the Federal Motor Carrier Safety Administration (FMCSA), uses this $14.2 million VSL (and proportional Maximum Abbreviated Injury Scale fractions for non-fatal crash injuries) in all benefit-cost evaluations.

The Department of Health and Human Services (HHS) updates its default regulatory valuation parameters annually through ASPE to govern analyses by the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), the Health Resources and Services Administration (HRSA), and the Centers for Disease Control and Prevention (CDC). Grounded in a criteria-driven meta-analysis of wage-risk and stated-preference studies calibrated to a 2013 base year, ASPE reports in its October 2026 technical appendix that adjusting the 2013 baseline for inflation to constant 2025 dollars yields $12.4 million. When ASPE combines that inflation adjustment with an income elasticity of 1.0, historical real earnings growth from 2013 through 2025, and a projected long-term real earnings growth rate of 1.117% per year for 2026 through 2040, the official HHS central VSL for 2026 equals $14.1 million (reflecting a 14% increase in real willingness to pay between 2013 and 2026).

Furthermore, because clinical and public health interventions frequently extend survival by a measurable number of years or improve physical functioning rather than averting an instantaneous accidental death, HHS ASPE calculates both a Value of a Statistical Life Year (VSLY) and a Value per Quality-Adjusted Life Year (VQALY). ASPE derives these metrics from the remaining life expectancy of a 40-year-old individual (matching the average age in the underlying VSL literature), who has 41.0 undiscounted years of remaining life expectancy, or 23.3 discounted life-years at a 3% annual discount rate. Incorporating age-varying population health-related quality-of-life (HRQL) scores yields 33.9 undiscounted remaining quality-adjusted life years (QALYs), or 19.6 discounted QALYs at a 3% discount rate. Dividing the year-specific VSL by these discounted denominators produces a 2026 HHS central VSLY of $607,402 (with a low bound of $283,454 and a high bound of $924,602) and a 2026 central VQALY of $722,068 (with a low bound of $336,965 and a high bound of $1,099,149). Over the projection horizon from 2026 to 2040, ASPE projects the central VSLY to rise in constant 2025 dollars from $607,402 to $709,602, and the central VQALY to rise from $722,068 to $843,562.

The Consumer Product Safety Commission (CPSC) issued a landmark regulatory update on April 18, 2024, publishing its Final Guidance for Estimating Value per Statistical Life in the Federal Register following public notice and review of draft CPSC VSL guidelines. Adopting the HHS ASPE adult baseline of $13.0 million in 2023 dollars and 2023 real income levels (equivalent to $14.1 million in 2026), the CPSC formally established a child VSL of $26.0 million in 2023 dollars, exactly double the adult rate, for all product safety analyses involving individuals under age 18.

The Environmental Protection Agency (EPA) maintains a baseline VSL recommendation of $7.4 million in 2006 dollars, derived from 26 peer-reviewed studies (21 wage-risk studies and five stated-preference studies) vetted by the EPA Science Advisory Board (SAB) Environmental Economics Advisory Committee. When updated to 2025 and 2026 dollars for CPI inflation and real income growth within the agency’s open-source environmental Benefits Mapping and Analysis Program (BenMAP) and its PM2.5 and ozone health benefits technical support documents, the EPA VSL equals approximately $13.6 million to $14.0 million per statistical death avoided. To clarify public communication, the EPA has also proposed supplementing VSL terminology with the Value of Mortality Risk (VMR), expressed in dollars per micro-risk (a one-in-1,000,000 annual risk change) per person per year, where a $13.6 million VSL equals $13.60 per micro-risk reduction.

The Federal Emergency Management Agency (FEMA), the Department of Homeland Security, and the Occupational Safety and Health Administration (OSHA) similarly align their benefit-cost modules with the DOT and HHS VSL frameworks, updating earlier $7.5 million to $10.0 million baselines to the current $13.2 million to $14.2 million range for flood mitigation grants, seismic retrofits, and workplace hazard standards.

The table below compares the official mortality valuation benchmarks and adjustment methodologies across primary United States federal agencies and global health economics bodies as of October 2026.

Ethical Disputes, Age Adjustments, and Global Disparities in Mortality Valuation

Placing a monetary figure on statistical survival sits at the center of intense philosophical, legal, and regulatory disputes. Because the chosen valuation method determines which environmental rules survive judicial and executive review, which medical treatments receive reimbursement, and how disaster mitigation grants are distributed across communities, changes in mortality valuation policy carry immediate life-and-death consequences.

Philosophical Critiques Versus Regulatory Discipline

Critics of benefit-cost orthodoxy challenge the premise that health and survival can be measured on the same monetary scale as industrial compliance costs. In What Money Can’t Buy: The Moral Limits of Markets, political philosopher Michael J. Sandel argues that extending market pricing into non-market spheres corrupts moral reasoning and treats civic obligations as tradable commodities. Legal scholars Frank Ackerman and Lisa Heinzerling similarly contend that deriving the value of a human life from workplace wage premiums conflates voluntary occupational bargains made by unionized male blue-collar workers with involuntary, uncompensated environmental hazards imposed on infants, pregnant women, and elderly residents living near industrial emitters.

A second ethical objection targets the practice of discounting future mortality benefits. When an agency regulates a persistent environmental carcinogen such as benzene, hexavalent chromium, or trichloroethylene, compliance costs are incurred immediately by industrial facilities, whereas the prevented fatal cancers occur after a 20-year to 30-year biological latency period. Applying a 3% annual discount rate reduces the present monetary value of a statistical life saved 25 years in the future by more than half, and applying a 7% discount rate reduces its present value by more than 80%. Critics argue that discounting future lives treats the survival of children and future generations as less valuable than present survival simply because their deaths occur later on the calendar.

Defenders of quantitative benefit-cost analysis, including former White House Office of Information and Regulatory Affairs administrator Cass R. Sunstein, respond that resource scarcity makes implicit valuation unavoidable. In a world of finite household incomes and constrained public budgets, refusing to use explicit VSL benchmarks does not make human life infinite in value; instead, it leaves life-saving decisions to political lobbying, media panic, and bureaucratic guesswork. Historical audits of federal regulations enacted without benefit-cost discipline revealed extreme inconsistencies in which agencies spent hundreds of millions of dollars per statistical life saved on minor industrial waste rules while neglecting low-cost highway, nutritional, and immunization rules that could have saved thousands of lives with the same resources.

The 2026 EPA Air Pollution Monetization Controversy

The real-world stakes of VSL accounting became sharply visible in January 2026 when a major methodological dispute erupted over the Environmental Protection Agency’s rulemaking practices. For more than three decades across both Republican and Democratic administrations, the EPA used BenMAP and its peer-reviewed VSL benchmark to quantify and monetize the premature deaths prevented by reducing fine particulate matter (PM2.5) and ground-level ozone. According to Office of Management and Budget summaries, monetized mortality reductions from EPA air quality rules accounted for the majority of all quantified monetary benefits produced by the entire federal regulatory apparatus.

In early 2026 the EPA proposed in its economic impact analysis for stationary combustion turbine emission standards to stop monetizing human health and mortality benefits from PM2.5 and ozone reductions, quantifying only the direct compliance costs borne by regulated power and industrial companies. As analyzed in a January 30, 2026 report by economists Bryan Hubbell and Alan Krupnick at Resources for the Future (RFF), the agency argued that epidemiological uncertainties in concentration-response functions below the National Ambient Air Quality Standards and uncertainties in point-estimate monetization justified omitting dollar benefit figures until modeling confidence improved.

Hubbell and Krupnick demonstrated in their rebuttal that the EPA’s decision contradicted OMB Circular A-4, the agency’s own 2024 Guidelines for Preparing Economic Analyses, and decades of reviews by the National Academies of Sciences, Engineering, and Medicine and the EPA Clean Air Scientific Advisory Committee. Because epidemiologists and environmental economists have already operationalized probability distributions, confidence intervals, and sensitivity analyses within BenMAP to account for uncertainty, refusing to monetize prevented deaths while continuing to monetize industry compliance costs effectively assigns a marginal monetary value of zero to prevented cardiopulmonary fatalities in net-benefit tables. That asymmetry tilts regulatory impact analyses systematically toward weaker pollution standards and illustrates why preserving transparent VSL monetization is widely defended by public health advocates as a vital protection for vulnerable communities.

Age Adjustments, Senior Discounts, and Child Risk Premiums

A second recurring controversy involves whether the value of a human life in regulatory analyses should vary with the age of the population protected. From a pure longevity perspective, preventing the fatal car crash of an 18-year-old preserves roughly 61 years of remaining life expectancy, whereas preventing the pneumonia death of an 88-year-old preserves roughly five years of remaining life expectancy. Moreover, theoretical lifecycle consumption models suggest that willingness to pay for a one-year survival probability peaks in middle age and declines somewhat in advanced age as remaining lifetime wealth and future years of life diminish.

When the EPA attempted to operationalize age-differentiated VSLs in 2002 and 2003 during analyses of the Clear Skies legislative proposal and non-road diesel engine standards, the agency applied a 37% downward adjustment, quickly dubbed the senior discount in congressional hearings, valuing statistical fatalities averted among Americans aged 65 and older at $2.3 million compared with $3.7 million for adults under age 65. Because fine particulate air pollution kills primarily older adults with chronic heart and lung disease, the 37% reduction sharply lowered the calculated benefits of clean air rules. Intense public backlash from older Americans and lawmakers forced the EPA to repudiate the senior discount in May 2003, establishing a lasting federal norm against discounting the lives of senior citizens in VSL calculations.

In current 2026 practice, federal agencies reconcile population uniformity with longevity sensitivity by reporting complementary metrics. The DOT ($14.2 million) and the EPA ($7.4 million in 2006 dollars) apply a single uniform VSL to every statistical fatality regardless of whether the victim is 20 or 80 years old. At HHS, ASPE provides both a uniform VSL ($14.1 million in 2026) and age-sensitive life-year metrics ($607,402 per VSLY and $722,068 per VQALY in 2026) so that clinical rules extending life expectancy by a known duration can be evaluated alongside binary accident-prevention rules.

At the opposite end of the age spectrum, upward valuation adjustments for children have gained formal federal adoption. Stated-preference surveys and revealed-preference studies of household spending on infant car seats, organic baby food, and pediatric medical care consistently find that parents value reducing fatal risks to their children at 1.5 to 2.7 times the value they place on reducing fatal risks to themselves. As documented in a Cambridge Core study of disposable lighter safety regulations in the Journal of Benefit-Cost Analysis, NHTSA invoked unquantified child valuation premiums when finalizing its rear-visibility camera mandate to prevent toddler backover fatalities, and the CPSC formally codified a 2.0-times multiplier in April 2024, establishing a $26.0 million child VSL alongside its $13.0 million adult VSL in 2023 dollars.

Dread Differentials, Altruism, and Global Valuation Inequality

Beyond age, regulatory economists also investigate whether the cause of death alters willingness to pay. In its mortality valuation white papers reviewed by the Science Advisory Board, the EPA has examined the cancer differential, defined as the additional premium people are willing to pay to avoid a protracted, painful death from malignancy compared with an instantaneous accidental fatality, as well as altruistic preferences, which capture citizens’ willingness to pay for public health rules that protect neighbors and fellow citizens in addition to themselves.

Most strikingly, because willingness to pay is constrained by ability to pay, income elasticity creates vast differences between domestic and international mortality valuations. Within the United States, federal agencies strictly forbid applying different VSLs to rich and poor citizens; doing so would violate equal protection norms and concentrate toxic waste and dangerous roads in low-income neighborhoods. Internationally national governments and multilateral development banks calibrate VSLs to national per capita income. In a comprehensive global modeling study published in January 2026 in the Bulletin of the World Health Organization, researchers calculated VSL benchmarks across 182 World Health Organization Member States covering 7.99 billion people (98.4% of the global population). The global average VSL in 2024 was 3.76 million international dollars, projected to increase by 159.8% to 9.77 million international dollars by 2100. Yet in low-income nations, income-adjusted VSL estimates remain a small fraction of the $14.1 million to $14.2 million United States benchmark, highlighting why cost-benefit analyses of global climate and infectious disease programs must be paired with distributional equity weights and direct cost-per-life-saved comparisons.

Leading Causes of Death in the United States: Final 2024 and Provisional 2025 Mortality Data

Assessing which government-funded programs can save the greatest number of lives requires examining the exact epidemiological profile of mortality in the United States. On January 29, 2026, the CDC National Center for Health Statistics released NCHS Data Brief No. 548, presenting final mortality data for calendar year 2024 compiled from death certificates filed across all 50 states and the District of Columbia through the National Vital Statistics System. Complementing that report, on October 27, 2026, the HHS Office of the Assistant Secretary for Planning and Evaluation published its analysis of 2025 mortality trends, evaluating NCHS provisional 2025 death counts alongside updated Census Bureau population denominators. Together, these two primary federal datasets provide an exact portrait of American mortality as of October 2026.

National Mortality Totals, Life Expectancy, and the Record-Low 2025 Death Rate

In 2024, exactly 3,072,666 resident deaths were registered in the United States, representing 18,298 fewer deaths than the 3,090,964 deaths recorded in 2023. Because the United States population simultaneously grew and aged, the age-adjusted death rate, which standardizes age-specific mortality rates to the year 2000 United States standard population distribution, fell by 3.8%, declining from 750.5 deaths per 100,000 standard population in 2023 to 722.1 deaths per 100,000 in 2024.

Driven by substantial mortality reductions in unintentional injuries, COVID-19, heart disease, cancer, and homicide, United States life expectancy at birth rose by 0.6 year in 2024 to 79.0 years, up from 78.4 years in 2023. Male life expectancy at birth increased by 0.7 year from 75.8 years in 2023 to 76.5 years in 2024, and female life expectancy at birth rose by 0.3 year from 81.1 years to 81.4 years, narrowing the female-to-male longevity gap by 0.4 year to 4.9 years. For Americans reaching age 65, remaining life expectancy increased by 0.2 year to 19.7 years overall (20.8 years for females, up 0.1 year, and 18.4 years for males, up 0.2 year).

In July 2026, NCHS Vital Statistics Rapid Release No. 44 reported 3,094,593 provisional resident deaths for calendar year 2025 and a headline provisional age-adjusted death rate of 689.2 deaths per 100,000 standard population, the lowest headline age-adjusted death rate ever recorded in United States history and 4.6% below the published 2024 rate of 722.1. In its October 27, 2026 technical decomposition, HHS ASPE demonstrated that comparing the published 2024 rate (722.1) with the provisional 2025 rate (689.2) combines mortality improvements with a concurrent revision in U.S. Census Bureau population methodology from Vintage 2024 (which used a blended base) to Vintage 2025 (which uses the enumerated 2020 Census and the Modified Age and Race Census file). When ASPE recalculated both 2024 and 2025 mortality using the common Vintage 2025 population denominator and August 20, 2026 CDC WONDER mortality files, the harmonized age-adjusted death rate fell from 703.9 per 100,000 in 2024 to 689.8 per 100,000 in 2025, a common-vintage reduction of 14.1 deaths per 100,000 (approximately 2.0%). That harmonized comparison confirmed that 2025 achieved the lowest age-adjusted death rate of the entire 2020 through 2025 period, with 87% of the net decline driven by four causes: unintentional injuries (contributing 4.23 deaths per 100,000, or 30% of the net decline), COVID-19 (4.01 per 100,000, or 28%), cancer (2.55 per 100,000, or 18%), and heart disease (1.57 per 100,000, or 11%), partially offset by a 1.57 per 100,000 increase in influenza and pneumonia mortality.

The Ten Leading Causes of Death in 2024

In the final 2024 NCHS mortality files, the 10 leading causes of death accounted for 70.9% of all deaths in the United States (2,179,957 fatalities out of 3,072,666), leaving 892,709 deaths (29.1%) in the residual all-other-causes category. Between 2023 and 2024, nine of the 10 leading causes remained in the top 10, whereas suicide moved into the 10th spot, replacing COVID-19, which dropped from the 10th leading cause in 2023 (49,932 underlying-cause deaths) to the 15th leading cause in 2024 (31,426 underlying-cause deaths, a 37.1% decline). Remarkably, every single one of the 10 leading causes of death recorded a statistically significant decrease in its age-adjusted death rate between 2023 and 2024.

The table below details the official final 2024 rankings, death counts, percentage shares of total mortality, and age-adjusted death rates per 100,000 United States standard population from NCHS Data Brief No. 548.

Clinical and Epidemiological Analysis of the Top Ten Causes

1. Diseases of the Heart (683,491 deaths; 22.2% of total): Coded under International Classification of Diseases, 10th Revision (ICD-10) rubrics I00 through I09, I11, I13, and I20 through I51, heart disease has ranked as the leading cause of death in the United States every year since 1950. Between 2023 and 2024, raw heart disease deaths rose slightly from 680,981 to 683,491 as the post-war Baby Boom cohort aged into older brackets, yet the age-adjusted heart disease death rate fell significantly by 2.8%, from 162.1 to 157.6 per 100,000. Coronary atherosclerosis, acute myocardial infarction, hypertensive heart disease, and heart failure account for the overwhelming majority of these deaths. As noted in the CDC FastStats mortality overview and chronic disease economic fact sheets, roughly half of all American adults have hypertension, and tens of millions have uncontrolled blood pressure or elevated low-density lipoprotein cholesterol, making pharmacological blood pressure control, statin therapy, sodium reduction, and smoking cessation the primary clinical levers to prevent premature cardiac fatalities.
2. Malignant Neoplasms, or Cancer (619,876 deaths; 20.2% of total): Coded under ICD-10 rubrics C00 through C97, cancer claimed 619,876 lives in 2024 compared with 613,352 in 2023. Like heart disease, raw cancer deaths increased due to demographic aging, whereas the age-adjusted cancer mortality rate declined by 1.7%, falling from 141.8 to 139.4 per 100,000 in 2024 and declining by another 2.55 per 100,000 in provisional 2025 data. Lung and bronchus cancer remains the single deadliest malignancy, followed by colorectal, pancreatic, breast, prostate, and liver cancers. Because cancer encompasses hundreds of distinct histologies and genetic driver mutations, public health strategies combine primary prevention (tobacco control, human papillomavirus and hepatitis B vaccination, radon and occupational carcinogen mitigation) with population screening (mammography, colonoscopy, fecal immunochemical testing, Pap and HPV cotesting, and low-dose computed tomography for heavy smokers) and targeted immunotherapies and antibody-drug conjugates, a clinical evolution explored in Taming Cancer: 21st Century Biology and the Future of Cancer Medicine.
3. Accidents, or Unintentional Injuries (197,449 deaths; 6.4% of total): Coded under ICD-10 rubrics V01 through X59 and Y85 through Y86, unintentional injuries dropped by 25,249 deaths from 222,698 in 2023 to 197,449 in 2024. The age-adjusted unintentional injury death rate plummeted by 14.4%, from 62.3 to 53.3 per 100,000, the largest percentage reduction among all 10 leading causes. Three mechanisms dominate this category: unintentional drug poisonings (overdoses), motor vehicle traffic crashes, and unintentional falls among older adults. Because drug overdoses and motor vehicle crashes disproportionately kill children, adolescents, and working-age adults under age 55, unintentional injuries represent the leading cause of death for Americans aged one to 44 and destroy more years of potential life before age 75 than almost any other category.
4. Cerebrovascular Diseases, or Stroke (166,852 deaths; 5.4% of total): Coded under ICD-10 rubrics I60 through I69, ischemic and hemorrhagic strokes caused 166,852 deaths in 2024, compared with 162,639 in 2023, as the age-adjusted stroke mortality rate decreased by 1.0% from 39.0 to 38.6 per 100,000. Hypertension is the single most important modifiable risk factor for both ischemic and intracerebral hemorrhagic stroke, alongside atrial fibrillation, diabetes, tobacco smoking, and carotid artery stenosis. Expanding mobile stroke units equipped with computed tomography scanners, intravenous thrombolytics (alteplase and tenecteplase), and endovascular mechanical thrombectomy networks directly prevents fatal brain infarction and permanent paralysis.
5. Chronic Lower Respiratory Diseases (145,643 deaths; 4.7% of total): Coded under ICD-10 rubrics J40 through J47, chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and asthma caused 145,643 deaths in 2024 (versus 145,357 in 2023), with the age-adjusted death rate falling 3.0% from 33.4 to 32.4 per 100,000. Cigarette smoking accounts for roughly eight out of 10 COPD deaths in the United States, compounded by ambient air pollution, occupational mineral and agricultural dusts, and respiratory viral exacerbations.
6. Alzheimer Disease (116,022 deaths; 3.8% of total): Coded under ICD-10 rubric G30, Alzheimer disease claimed 116,022 lives in 2024 (compared with 114,034 in 2023), with an age-adjusted death rate of 27.1 per 100,000, down 2.2% from 27.7 in 2023. Although disease-modifying anti-amyloid monoclonal antibodies have entered clinical practice, population-level prevention focuses on midlife hypertension control, hearing loss correction, physical activity, diabetes management, and supportive geriatric and palliative care models that prevent fatal aspiration pneumonia and sepsis.
7. Diabetes Mellitus (94,445 deaths; 3.1% of total): Coded under ICD-10 rubrics E10 through E14, diabetes caused 94,445 underlying-cause deaths in 2024 (down from 95,190 in 2023), as the age-adjusted rate fell 3.1% from 22.4 to 21.7 per 100,000. Beyond deaths coded directly to diabetic ketoacidosis, hyperosmolar coma, or diabetic vascular complications, diabetes is listed as a contributing cause on hundreds of thousands of additional death certificates involving myocardial infarction, stroke, and renal failure. Continuous glucose monitoring, affordable insulin caps, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists have begun bending the trajectory of diabetic cardiovascular and renal mortality.
8. Nephritis, Nephrotic Syndrome, and Nephrosis, or Kidney Disease (55,081 deaths; 1.8% of total): Coded under ICD-10 rubrics N00 through N07, N17 through N19, and N25 through N27, acute and chronic kidney disease caused 55,081 deaths in 2024 (down from 55,253 in 2023), with the age-adjusted rate declining 3.8% from 13.1 to 12.6 per 100,000, the second-largest percentage rate drop among the top 10 causes after unintentional injuries. Expanding access to deceased-donor and living-donor kidney transplantation and SGLT2 inhibitor therapy represents the primary clinical pathway to avert end-stage renal mortality.
9. Chronic Liver Disease and Cirrhosis (52,274 deaths; 1.7% of total): Coded under ICD-10 rubrics K70 and K73 through K74, chronic liver disease caused 52,274 deaths in 2024 (compared with 52,222 in 2023), with the age-adjusted death rate decreasing 2.3% from 13.0 to 12.7 per 100,000. Curative direct-acting antiviral therapies for hepatitis C virus (HCV), hepatitis B immunization, alcohol excise taxation and addiction pharmacotherapy, and metabolic fatty liver interventions provide proven avenues to reduce cirrhosis deaths.
10. Intentional Self-Harm, or Suicide (48,824 deaths; 1.6% of total): Coded under ICD-10 rubrics U03, X60 through X84, and Y87.0, suicide caused 48,824 deaths in 2024 (down from 49,316 in 2023), with the age-adjusted suicide rate falling 2.8% from 14.1 to 13.7 per 100,000. Together with drug overdoses and alcohol-related cirrhosis, suicide forms the triad of mortality termed deaths of despair by Princeton economists Anne Case and Angus Deaton in studies of working-age mortality, requiring integrated behavioral crisis intervention, lethal-means safety, and economic stabilization.

Demographic Disparities, Infant Mortality, and the Synthetic Opioid Reversal

National mortality averages obscure significant variations across age cohorts, racial and ethnic populations, and specific injury mechanisms. Disaggregating the 2024 and 2025 CDC and HHS datasets reveals exactly where premature deaths are concentrated and why the rapid reversal of synthetic opioid mortality between 2023 and 2025 offers a blueprint for high-return federal public health investment.

Age-Specific Mortality Rates Across the Lifespan

In 2024, age-specific death rates decreased statistically significantly from 2023 across every age bracket aged one year and older except for children aged five to 14, whose death rate remained statistically unchanged at 14.5 deaths per 100,000 population (5,940 deaths in 2024 compared with 6,005 deaths and a 14.7 rate in 2023). The complete age-specific breakdown from NCHS Data Brief No. 548 demonstrates the magnitude of survival gains among younger and working-age Americans:

• Ages 1 to 4: Total deaths declined from 4,059 in 2023 to 3,843 in 2024, reducing the age-specific mortality rate by 6.2% from 27.3 to 25.6 deaths per 100,000 population.
• Ages 5 to 14: Total deaths numbered 5,940 in 2024 (14.5 per 100,000), the lowest mortality rate of any stage of the human lifespan.
• Ages 15 to 24: Total deaths fell by 3,758 from 33,711 in 2023 to 29,953 in 2024, driving a 12.9% decrease in the age-specific death rate from 76.8 to 66.9 per 100,000.
• Ages 25 to 34: Total deaths plunged by 9,622 in a single year, falling from 67,449 in 2023 to 57,827 in 2024 and lowering the age-specific death rate by 15.9% from 148.1 to 124.5 per 100,000, the largest proportional improvement of any age group in the United States.
• Ages 35 to 44: Total deaths dropped by 7,906 from 105,336 in 2023 to 97,430 in 2024, reducing the death rate by 9.9% from 237.3 to 213.9 per 100,000.
• Ages 45 to 54: Total deaths fell from 166,773 in 2023 to 157,770 in 2024, cutting the age-specific death rate by 6.0% from 411.8 to 386.9 per 100,000.
• Ages 55 to 64: Total deaths declined by 18,338 from 376,534 in 2023 to 358,196 in 2024, reducing the death rate by 4.4% from 899.6 to 859.8 per 100,000.
• Ages 65 to 74: Although raw deaths edged up from 627,680 to 628,416 due to cohort expansion, the age-specific death rate fell by 2.0% from 1,809.6 to 1,772.9 per 100,000.
• Ages 75 to 84: Raw deaths rose from 798,188 to 822,944 as the population aged, while the age-specific death rate fell by 1.9% from 4,345.5 to 4,264.0 per 100,000.
• Ages 85 and Older: Raw deaths numbered 890,240 in 2024 compared with 885,004 in 2023, while the age-specific death rate declined by 3.2% from 14,285.8 to 13,834.0 per 100,000.

As HHS ASPE proved in its October 27, 2026 common-vintage decomposition of the 2024 to 2025 mortality decline, working-age adults aged 25 to 64 accounted for slightly more than half of the entire national age-adjusted mortality improvement between 2024 and 2025 once Census Vintage 2025 denominators are applied consistently, whereas adults aged 65 and older accounted for roughly 42% of the improvement.

Racial and Ethnic Mortality Disparities and Misclassification Adjustments

NCHS mortality surveillance also documents persistent disparities across racial and Hispanic-origin groups, even after correcting for death-certificate reporting inaccuracies. Validation studies linking census records with death certificates show that funeral directors and certifying officials misclassify race and Hispanic origin on death certificates at rates that cause unadjusted vital statistics to underestimate death rates by 34% for non-Hispanic American Indian and Alaska Native people and by 3% for Hispanic and non-Hispanic Asian people.

Using NCHS misclassification-corrected rates for 2024, age-adjusted mortality decreased significantly from 2023 for every single racial and ethnic group for both sexes, yet wide gaps remained:

• Non-Hispanic American Indian and Alaska Native Population: Males recorded the highest age-adjusted death rate in the nation at 1,213.0 deaths per 100,000 standard population in 2024 (11,356 deaths, down 5.1% from 1,277.7 in 2023), and females recorded 872.7 per 100,000 (9,568 deaths, down 5.2% from 920.3).
• Non-Hispanic Black Population: Males recorded the second-highest rate at 1,094.9 per 100,000 (201,255 deaths, down 4.9% from 1,151.6 in 2023), and females recorded 727.2 per 100,000 (179,690 deaths, down 3.5% from 753.6).
• Non-Hispanic White Population: Males recorded an age-adjusted rate of 871.1 per 100,000 (1,177,767 deaths, down 3.9% from 906.4 in 2023), and females recorded 646.6 per 100,000 (1,112,581 deaths, down 2.4% from 662.8).
• Hispanic Population: Males recorded an age-adjusted rate of 651.9 per 100,000 (145,230 deaths, down 5.9% from 692.8 in 2023), and females recorded 454.6 per 100,000 (115,569 deaths, down 3.8% from 472.4).
• Non-Hispanic Asian Population: Males recorded an age-adjusted rate of 454.2 per 100,000 (45,118 deaths, down 4.6% from 476.1 in 2023), and females recorded the lowest mortality rate of any demographic group at 317.6 per 100,000 (42,610 deaths, down 5.1% from 334.6).

Infant Mortality and Neonatal Causes of Death in 2024

Infant mortality is tracked separately in national vital statistics as the number of deaths among infants under one year of age per 100,000 live births. In 2024, 20,050 infant deaths occurred in the United States, 95 fewer than the 20,145 infant deaths registered in 2023. The national infant mortality rate stood at 552.5 infant deaths per 100,000 live births in 2024, a slight numerical decline from 560.2 in 2023 that did not reach statistical significance.

Ten leading causes accounted for 65.8% of all infant deaths in 2024:

1. Congenital malformations, deformations, and chromosomal abnormalities (ICD-10 codes Q00–Q99): 4,061 deaths (20.3% of infant deaths; rate of 111.9 per 100,000 live births).
2. Disorders related to short gestation and low birth weight (P07): 2,941 deaths (14.7%; rate of 81.0).
3. Sudden infant death syndrome, or SIDS (R95): 1,351 deaths (6.7%; rate of 37.2, a statistically significant 7.5% decrease from 40.2 in 2023).
4. Unintentional injuries (V01–X59): 1,245 deaths (6.2%; rate of 34.3), primarily accidental suffocation and strangulation in bed and motor vehicle crashes.
5. Newborn affected by maternal complications of pregnancy (P01): 1,193 deaths (6.0%; rate of 32.9).
6. Bacterial sepsis of newborn (P36): 603 deaths (3.0%; rate of 16.6).
7. Newborn affected by complications of placenta, cord, and membranes (P02): 594 deaths (3.0%; rate of 16.4).
8. Respiratory distress of newborn (P22): 453 deaths (2.3%; rate of 12.5).
9. Diseases of the circulatory system (I00–I99): 376 deaths (1.9%; rate of 10.4), moving up from the 10th to the ninth leading cause in 2024.
10. Intrauterine hypoxia and birth asphyxia (P20–P21): 362 deaths (1.8%; rate of 10.1).

Because congenital anomalies, prematurity, maternal pregnancy complications, and sleep-related suffocation account for more than half of all infant deaths, maternal-fetal health interventions such as universal prenatal care, folic acid fortification, progesterone therapy for short cervix, neonatal intensive care surfactant and sepsis protocols, and safe-sleep bassinet and parent education programs offer direct, measurable mechanisms to avert infant deaths, each of which carries a $26.0 million valuation under the CPSC child VSL framework.

Anatomy of the 2024 and 2025 Synthetic Opioid Overdose Reversal

The single most important public health finding in the 2026 CDC and HHS mortality reports is the dramatic turnaround in United States drug overdose deaths. As documented by Matthew F. Garnett and Arialdi M. Miniño in NCHS Data Brief No. 549, United States drug overdose mortality climbed relentlessly for a decade, rising from 47,055 deaths in 2014 (an age-adjusted rate of 14.7 per 100,000) to 63,632 in 2016 (19.8), 70,630 in 2019 (21.6), 91,799 in 2020 (28.3), 106,699 in 2021 (32.4), and a historic peak of 107,941 deaths in 2022 (32.6 per 100,000), before edging down slightly to 105,007 deaths in 2023 (31.3 per 100,000).

In 2024, total United States drug overdose deaths fell by 25,623 deaths in a single year to 79,384 deaths, lowering the national age-adjusted drug overdose death rate by 26.2% from 31.3 to 23.1 deaths per 100,000 standard population. Of the 79,384 drug overdose deaths in 2024, 91.6% were classified as unintentional poisonings (ICD-10 codes X40–X44), 5.6% as intentional self-harm suicides (X60–X64), 2.7% as undetermined intent (Y10–Y14), and less than 1.0% as homicides (X85). Male overdose deaths dropped by 19,113 (from 74,189 to 55,076, a 27.3% rate decrease from 44.3 to 32.2 per 100,000), and female overdose deaths dropped by 6,510 (from 30,818 to 24,308, a 23.0% rate decrease from 18.3 to 14.1).

Toxicology decompositions by multiple-cause-of-death drug codes reveal that the collapse of illicitly manufactured fentanyl fatalities drove this historic improvement:

• Any Opioid (ICD-10 codes T40.0–T40.4, T40.6): Fell from 79,358 deaths in 2023 (24.0 per 100,000) to 54,045 deaths in 2024 (16.0 per 100,000), a 33.3% rate reduction.
• Synthetic Opioids Other Than Methadone (T40.4, primarily fentanyl and fentanyl analogs): Plunged by 25,041 deaths in 2024, dropping from 72,776 deaths in 2023 (22.2 per 100,000) to 47,735 deaths in 2024 (14.3 per 100,000), a 35.6% decrease in the age-adjusted rate.
• Natural and Semisynthetic Opioids (T40.2, such as oxycodone, hydrocodone, and morphine): Declined from 10,112 deaths (2.9 per 100,000) to 7,989 deaths (2.3 per 100,000), a 20.7% rate drop.
• Heroin (T40.1): Declined from 3,984 deaths (1.2 per 100,000) to 2,743 deaths (0.8 per 100,000), a 33.3% rate drop.
• Methadone (T40.3): Declined from 3,355 deaths (1.0 per 100,000) to 3,229 deaths (0.9 per 100,000), a 10.0% rate drop.
• Psychostimulants With Abuse Potential (T43.6, primarily methamphetamine): Declined from 34,855 deaths (10.6 per 100,000) to 28,722 deaths (8.5 per 100,000), a 19.8% rate drop.
• Cocaine (T40.5): Declined from 29,449 deaths (8.6 per 100,000) to 21,945 deaths (6.3 per 100,000), a 26.7% rate drop.

Even more encouragingly, the October 27, 2026 HHS ASPE report confirmed that unintentional T40.4 synthetic opioid deaths fell by an additional 20.7% in 2025, declining from 45,917 unintentional T40.4 deaths in 2024 to 36,406 in 2025 (a reduction of 2.98 deaths per 100,000 on a common-vintage basis, accounting for 96% of the entire 2025 overdose decline). ASPE identified two complementary policy mechanisms behind this two-year drop of more than 36,000 annual fentanyl deaths: first, federal treatment and harm-reduction expansion under the 2018 and 2025 SUPPORT for Patients and Communities Acts, the March 2023 FDA approval of over-the-counter 4-milligram naloxone nasal spray, SAMHSA’s distribution of over 10 million opioid reversal doses, and the 2023 Mainstreaming Addiction Treatment (MAT) Act’s elimination of the federal DATA-waiver restriction on prescribing buprenorphine; and second, multi-agency precursor chemical controls and cartel sanctions that caused average DEA-analyzed fentanyl powder purity to fall from 19.5% in fiscal year 2023 to 10.3% in fiscal year 2025 and reduced the share of seized counterfeit pills containing a potentially lethal fentanyl dose from 76% to 29%.

Federal Public Health, Clinical, and Behavioral Interventions: Costs and Lives Saved

The empirical record of United States public health programs demonstrates that the federal government does not face a uniform price tag to prevent premature death. Whereas regulatory mandates at the margin are authorized up to $14.1 million or $14.2 million per statistical life saved, direct public health, clinical, and behavioral grant programs administered by the CDC, SAMHSA, HRSA, and CMS routinely save lives for a few thousand to a few hundred thousand dollars per fatality averted.

The Empirical Hierarchy of Life-Saving Cost-Effectiveness

To evaluate how government programs compare in life-saving efficiency, health economists distinguish between benefit-cost analysis (BCA), which monetizes all outcomes using the VSL or VSLY, and cost-effectiveness analysis (CEA), which divides net programmatic cost by physical health outcomes such as lives saved, life-years gained, or quality-adjusted life years (QALYs) gained. As outlined in the CDC POLARIS Cost-Benefit and POLARIS Cost-Effectiveness frameworks, cost-effectiveness ratios allow policymakers to rank competing interventions directly by their dollar cost per death averted.

The most comprehensive comparative survey of life-saving interventions in the United States was compiled by Tammy O. Tengs and colleagues at the Harvard Center for Risk Analysis and published in Risk Analysis. Evaluating 587 distinct interventions across health care, injury prevention, and environmental regulation, the researchers documented that the median intervention cost $42,000 per life-year saved in base-year dollars (equivalent to roughly $90,000 per life-year, or $1.2 million to $1.8 million per statistical life saved in 2026 dollars). Across categories costs spanned more than six orders of magnitude:

• Clinical and Preventive Medicine: Median cost of $19,000 per life-year saved, with childhood immunizations, prenatal care, hypertension pharmacotherapy, and targeted cancer screenings frequently achieving cost-saving status (net cost below zero) or costing $5,000 to $50,000 per life-year gained.
• Fatal Injury Reduction: Median cost of $29,000 per life-year saved, led by smoke detectors, child safety seats, motorcycle and bicycle helmets, seatbelt enforcement, and highway rumble strips.
• Occupational and Environmental Toxin Control: Median cost of $4.2 million per life-year saved, reflecting the high capital expense of industrial scrubbing and site remediation when applied to low ambient concentration exposures.

Vaccines for Children (VFC) and Routine Immunization

Within the domestic federal budget, the Vaccines for Children (VFC) Program, enacted by Congress under the Omnibus Budget Reconciliation Act of 1993 and launched by the CDC in October 1994, represents the gold standard of life-saving fiscal efficiency. Created after the 1989 to 1991 United States measles resurgence disproportionately killed and hospitalized unvaccinated low-income preschool children, VFC entitles all children aged 18 and younger who are Medicaid-eligible, uninsured, underinsured, or American Indian or Alaska Native (roughly half of all American children) to receive Advisory Committee on Immunization Practices (ACIP) recommended vaccines at no out-of-pocket cost.

In an authoritative August 2024 CDC Morbidity and Mortality Weekly Report study summarized by Children’s Mercy clinical researchers, CDC health economists modeled the cumulative health and economic impact of routine childhood vaccination across 30 annual cohorts of children born in the United States from 1994 through 2023. Over those three decades, routine immunization against measles, mumps, rubella, polio, diphtheria, tetanus, pertussis, Haemophilus influenzae type b, hepatitis A and B, varicella, rotavirus, and pneumococcal disease prevented 508 million lifetime illnesses (including 100 million measles and varicella cases and 5,000 tetanus cases), averted 32 million hospitalizations, and saved 1,129,000 lives (an average of 37,633 premature deaths prevented per annual birth cohort).

Economically, the 1994 to 2023 immunization cohorts generated $2.7 trillion in net societal savings, including more than $540 billion in direct medical treatment costs avoided, meaning the program saves money as well as lives. Even if an analyst ignores the $2.7 trillion in medical and productivity savings and divides the gross annual federal VFC and Section 317 vaccine purchase and immunization infrastructure budget (approximately $6.8 billion to $7.5 billion per year) by 37,633 prevented deaths per annual cohort, the gross federal budgetary expenditure is roughly $180,000 to $200,000 per life saved. Furthermore, closing the remaining coverage gap identified by the CDC (where combined seven-vaccine series completion by age 24 months is 61% among VFC-eligible children living below the poverty line compared with 75% among non-VFC privately insured children) through community health worker outreach and clinic reminders costs an estimated $15,000 to $40,000 per incremental life saved.

SAMHSA Opioid Response, Naloxone Saturation, and Addiction Treatment

Targeting working-age mortality from unintentional drug poisonings, the Substance Abuse and Mental Health Services Administration (SAMHSA) administers the State Opioid Response (SOR) and Tribal Opioid Response (TOR) grant programs alongside the Substance Use Prevention, Treatment, and Recovery Services Block Grant. In September 2025, HHS awarded over $1.5 billion in fiscal year 2025 SOR and TOR continuation grants, followed by $281 million in July 2026 for overdose reversal and mental health training and $250 million in September 2026 for community addiction recovery and crisis stabilization, operating within an overall SAMHSA budget framework of approximately $7.5 billion to $8.1 billion.

Through SOR and TOR funding, state and tribal grantees have distributed more than 10 million doses of FDA-approved opioid overdose reversal medications (primarily intranasal naloxone and nalmefene) and documented hundreds of thousands of direct overdose reversals in Congressional reports, including 90,204 reversals in the 2021 SOR Report to Congress and 256,985 reversals in the 2022 SOR Report to Congress. Because a two-dose carton of generic or over-the-counter intranasal naloxone costs state bulk purchasers roughly $24 to $45, and clinical epidemiological models estimate that one fatal opioid overdose is averted for every 50 to 250 community naloxone kits distributed to active opioid users, lay bystanders, and first responders, targeted Opioid Overdose Education and Naloxone Distribution (OEND) saves a statistical human life for $3,000 to $15,000. When paired with low-barrier initiation of buprenorphine or methadone maintenance therapy (which cuts all-cause and overdose mortality among patients with opioid use disorder by 50% to 70% at an annual clinical cost of $4,500 to $7,000 per patient), comprehensive federal opioid response programs save lives at a blended cost of $15,000 to $35,000 per fatality prevented.

The 988 Suicide and Crisis Lifeline and Behavioral Crisis Stabilization

To address the 48,824 annual suicide deaths that returned suicide to the 10th leading cause of death in 2024, SAMHSA oversees the 988 Suicide and Crisis Lifeline, transitioned from the 10-digit National Suicide Prevention Lifeline in July 2022 under the National Suicide Hotline Designation Act. In 2025, the 988 Lifeline handled more than 8 million calls, texts, and chats from Americans experiencing acute suicidal ideation or substance use crises. On January 13, 2026, SAMHSA announced a $231 million grant opportunity for the national 988 Lifeline administrator under its fiscal year 2026 NOFO schedule, operating within roughly $500 million to $530 million in annual federal 988 appropriations, complemented by rising state telecommunications fee allocations documented across 306 state-year budgets from 2021 to 2026 in a September 2026 JAMA Network study and KFF policy tracking.

Published health economic evaluations of suicide crisis lines, post-crisis telephone follow-up programs, mobile behavioral crisis response teams, and emergency department safety planning demonstrate that structured crisis intervention reduces repeat suicide attempts by 20% to 45% among high-risk callers, yielding an estimated cost of $20,000 to $65,000 per suicide death averted.

CDC Tobacco Control, Cancer Screening, Hypertension, and Kidney Transplant Reforms

Across the chronic diseases that cause more than two-thirds of all American deaths, four targeted federal programs demonstrate exceptional cost-effectiveness:

1. CDC National Tobacco Control Program (NTCP): Funded at roughly $240 million annually through the CDC Office on Smoking and Health, the NTCP supports state tobacco quitlines and the national Tips From Former Smokers media campaign. As documented in the June 2025 American Cancer Society fact sheet, the Tips campaign is rated a public health best buy, costing less than $400 per life-year saved and under $4,000 per premature smoking-attributable death averted. State-level synthetic-control econometric evaluations published in Tobacco Control confirm that every $1 of public tobacco control expenditure reduces smoking-attributable healthcare costs by nearly $11 and generates $113 in monetized premature mortality reductions.
2. CDC National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and Colorectal Cancer Control Program: Operating on combined annual federal appropriations of approximately $240 million to $260 million, these programs fund free mammograms, diagnostic breast imaging, Pap smears, HPV testing, fecal immunochemical tests, and colonoscopies for low-income, uninsured, and underinsured adults. As reported by the CDC Breast Cancer Priority and Cervical Cancer Priority evaluations, biennial mammography for women aged 50 to 74 reduces breast cancer mortality by 26%, averting seven deaths for every 1,000 women screened, and detects tumors at localized stages where five-year survival exceeds 99% compared with 33% for distant metastasis. Across uninsured cohorts, federal cancer screening and diagnostic navigation programs save lives at an estimated cost of $25,000 to $75,000 per cancer death averted.
3. Million Hearts and Community Hypertension Control Initiatives (CDC/HRSA): Funded through CDC chronic disease grants and HRSA Federally Qualified Health Centers (which serve over 31 million low-income patients on roughly $5.8 billion in combined discretionary and mandatory funding), team-based hypertension management provides generic angiotensin-converting enzyme inhibitors, calcium channel blockers, thiazide diuretics, and home blood pressure monitors at a clinical cost of $150 to $400 per patient per year. Reducing systolic blood pressure by 10 millimeters of mercury in hypertensive adults reduces stroke risk by 27% and coronary heart disease events by 17%, saving a statistical life for $15,000 to $45,000.
4. CMS Organ Procurement Organization (OPO) Accountability and Advancing American Kidney Health: As HHS ASPE established in its October 20, 2026 evaluation, revising CMS conditions for coverage to benchmark OPOs against objective death-certificate donor potential increased annual United States kidney transplants from a pre-2019 growth rate of 2.6% to 2.8% (reaching 27,574 transplants in 2025, with donation after circulatory death rising from 21% in 2018 to 44% in 2024). Associated with 1,055 to 2,110 additional kidney transplants per year (23,214 to 46,428 cumulative transplants over 2019 through 2040), the reform generates 147,410 to 294,819 life-years gained, 21,821 to 43,643 QALYs gained, and $103 billion to $206 billion in economic benefits ($4.7 million per transplant in 2026: $3.9 million in longevity gains at the $607,402 VSLY, $0.68 million in morbidity QALY gains, and $0.12 million in avoided dialysis time) while achieving near-zero net Medicare expenditure or net lifetime medical savings of up to $36,667 per transplant compared with chronic thrice-weekly dialysis.

The table below summarizes the annual federal budgets and empirical cost-per-life-saved ranges for major United States government domestic and international life-saving programs.

Transportation Infrastructure, Vehicle Mandates, and Environmental Rulemaking

In addition to clinical and behavioral health grants, the federal government saves thousands of lives each year through physical highway engineering programs, motor vehicle crash-avoidance standards, and Clean Air Act pollution controls. Because civil engineering construction and fleet-wide automotive hardware installations require substantial capital outlays, these programs typically operate in the middle tier of cost-effectiveness, saving statistical lives for $130,000 to $3.0 million per fatality prevented.

Federal Highway Engineering and the Highway Safety Improvement Program

Motor vehicle traffic crashes claim approximately 39,000 to 41,000 lives annually in the United States, representing the second-largest component of unintentional injury mortality after drug poisonings. Under the Infrastructure Investment and Jobs Act (IIJA), the Federal Highway Administration (FHWA) administers the Highway Safety Improvement Program (HSIP), a core federal-aid program codified at 23 U.S.C. 148 to achieve significant reductions in traffic fatalities and serious injuries on all public roads, including non-state-owned county roads and tribal corridors. As documented in the FHWA HSIP national reports and FY 2025 computational tables, HSIP distributes more than $3.0 billion to $3.3 billion annually in formula funding to state departments of transportation.

Federal law requires every state to develop a data-driven Strategic Highway Safety Plan and evaluate candidate roadway projects using empirical Crash Modification Factors (CMFs) cataloged in the FHWA Crash Modification Factors Clearinghouse. A CMF represents the multiplicative ratio of expected crashes after implementing a countermeasure compared with baseline crashes without the countermeasure (for example, a CMF of 0.30 indicates a 70% crash reduction). Across the 28 FHWA Proven Safety Countermeasures, four categories of physical infrastructure investment demonstrate exceptionally low costs per life saved:

• Longitudinal Rumble Strips and Stripes: Milling continuous or sinusoidal rumble strips along two-lane rural highway centerlines and paved shoulders alerts drowsy or distracted motorists through tactile vibration and audible noise before a vehicle drifts into oncoming lanes or off the roadway embankment. Centerline rumble strips reduce fatal and injury head-on and opposite-direction sideswipe crashes by 44% on rural two-lane roads, and shoulder rumble strips reduce single-vehicle run-off-road fatal and injury crashes by 36%. Because milling rumble strips costs only $2,000 to $6,000 per linear mile, targeted installations on high-crash rural corridors avert fatalities for $50,000 to $150,000 per life saved.
• Median Cable and Concrete Barriers: Installing high-tension three-cable or four-cable barriers along wide, traversable medians on divided multi-lane highways intercepts errant vehicles without the severe deceleration forces of rigid concrete walls, eliminating up to 90% of cross-median fatal head-on collisions at an amortized capital cost of $200,000 to $500,000 per prevented fatality.
• Modern Roundabout Conversions: Converting traditional stop-controlled or signalized four-way intersections into modern roundabouts eliminates high-speed left-turn and right-angle (T-bone) impact geometry, forcing traffic to yield and circulate at 15 to 25 miles per hour. FHWA evaluations confirm that converting a two-way stop-controlled rural intersection into a single-lane roundabout reduces fatal and incapacitating injury crashes by 82%, and converting a signalized urban intersection into a roundabout reduces fatal and injury crashes by 78%. At a construction cost of $1.5 million to $4.0 million per intersection with a 25-year service life, roundabouts at high-crash junctions save lives for $400,000 to $1.2 million per statistical fatality averted.
• Systemic Pedestrian and Vulnerable Road User Infrastructure: Installing Pedestrian Hybrid Beacons (HAWK signals, which reduce pedestrian crashes by 55% and fatal and serious injury crashes by 15%), raised median refuge islands (reducing pedestrian crashes by 46% to 56%), rectangular rapid-flashing beacons, leading pedestrian signal intervals, and four-lane-to-three-lane road diets (reducing total crashes by 19% to 47%) saves lives across urban arterials for $300,000 to $1.5 million per fatality prevented.

The aggregate life-saving power of systematic HSIP allocation is quantified in the FHWA HSIP Evaluation Guide, which found in a statewide optimization model for Texas that an average annual investment of $540 million directed strictly to the highest-yield highway safety projects could save more than 540 lives each year, an average cost of $1.0 million per statistical life saved. Measured against the DOT’s $14.2 million VSL benchmark, every $1.0 million invested in proven highway engineering generates $14.2 million in monetized mortality benefits alone, before counting prevented spinal cord and traumatic brain injuries.

Motor Vehicle Safety Standards and Automatic Emergency Braking

Alongside roadway geometry, the National Highway Traffic Safety Administration regulates motor vehicle crashworthiness and crash-avoidance technology through Federal Motor Vehicle Safety Standards (FMVSS). On May 9, 2024, NHTSA published its landmark final rule establishing FMVSS No. 127 for Automatic Emergency Braking (AEB) systems on all light passenger vehicles weighing 10,000 pounds or less, with mandatory compliance required by September 1, 2029.

Unlike voluntary industry agreements signed in 2016 that required only low-speed forward collision braking in daylight, FMVSS No. 127 mandates that all passenger cars, pickup trucks, vans, and sport utility vehicles automatically apply the brakes to prevent rear-end collisions with lead vehicles at speeds up to 62 miles per hour (and up to 90 miles per hour when driver braking is assisted), and detect and brake automatically for pedestrians across both daylight and unlit nighttime roadway conditions at speeds up to 45.3 miles per hour. In its Final Regulatory Impact Analysis, NHTSA calculated that once the new vehicle fleet turns over, FMVSS No. 127 will save at least 362 lives and mitigate 24,321 non-fatal injuries every year. At an incremental annualized radar, camera, electronic control unit, and software compliance cost of approximately $354 million across the 15.5-million-vehicle annual United States sales fleet (roughly $82 per vehicle for manufacturers not already meeting the higher night-pedestrian specification), the rule’s gross cost per prevented fatality is approximately $978,000 per life saved (and even lower once injury-mitigation savings and avoided property damage are credited), yielding net societal benefits exceeding $5.0 billion annually under the $14.2 million DOT VSL.

Clean Air Act Particulate Matter Standards Versus Toxic Remediation

Within the Environmental Protection Agency, cost-effectiveness varies dramatically between ambient air quality standards that protect hundreds of millions of residents simultaneously and site-specific hazardous waste cleanups that affect small local populations.

On February 7, 2024, the EPA finalized its revised standard for the annual health-based National Ambient Air Quality Standard (NAAQS) for fine particulate matter (PM2.5), lowering the allowable annual average soot concentration from 12.0 micrograms per cubic meter to 9.0 micrograms per cubic meter. Because long-term epidemiological cohorts (including the Harvard Six Cities Study, the American Cancer Society Cancer Prevention Study II, and Medicare administrative cohorts covering more than 60 million older Americans) demonstrate a linear, no-threshold causal relationship between chronic PM2.5 inhalation and fatal ischemic heart disease, stroke, lung cancer, and COPD exacerbations, lowering ambient PM2.5 across metropolitan nonattainment counties reduces mortality across a massive population denominator. In its PM2.5 NAAQS overview and Regulatory Impact Analysis, the EPA projected that meeting the 9.0 microgram standard in 2032 will avoid up to 4,500 premature deaths, 800,000 cases of asthma symptoms, and 290,000 lost workdays every year. Against estimated annual engineering compliance costs of approximately $590 million in 2032, the rule generates up to $46 billion in net health benefits ($77 in health benefits per $1 spent), corresponding to a compliance cost of roughly $131,000 per premature death avoided.

In sharp contrast, regulations under the Comprehensive Environmental Response, Compensation, and Liability Act (Superfund), the Resource Conservation and Recovery Act, or specialized hazardous air pollutant rules targeting trace industrial solvents often exhibit costs ranging from $15 million to over $100 million per statistical cancer death averted. Because the baseline lifetime excess cancer risk near a remediated industrial parcel may be one in 100,000 across a neighboring population of only 5,000 residents, spending $50 million on soil excavation and groundwater pump-and-treat systems averts only 0.05 statistical deaths, yielding an implied cost of $1.0 billion per statistical life saved. This thousand-fold spread within environmental regulation underscores why reallocating funds toward high-exposure particulate, cardiovascular, and infectious disease interventions saves vastly more human lives than indiscriminate regulatory spending.

Global Health Appropriations and International Mortality Reduction Benchmarks

When the analytical scope expands beyond domestic borders to United States government-funded global health programs, the dollar cost required to save a single human life falls by two to three orders of magnitude. Because infectious diseases such as malaria, human immunodeficiency virus (HIV), tuberculosis, vaccine-preventable childhood illnesses, and diarrheal dehydration remain leading causes of death in low-income and lower-middle-income nations, proven medical commodities costing a few dollars per dose can prevent premature death among infants, children, and young adults who have 50 to 65 years of remaining life expectancy.

The President’s Emergency Plan for AIDS Relief (PEPFAR)

Launched in January 2003 and authorized by Congress under the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 (Public Law 108-25), the President’s Emergency Plan for AIDS Relief (PEPFAR) is the largest financial commitment by any nation in history to combat a single disease. As documented in a comprehensive May 22, 2026 policy report by KFF Global Health Policy, total Congressional appropriations for PEPFAR have exceeded $130 billion from fiscal year 2004 through fiscal year 2026. In the Consolidated Appropriations Act for fiscal year 2026 (Public Law 119-75, enacted in February 2026), Congress appropriated $6.0 billion for PEPFAR, comprising $4.7 billion for bilateral HIV programs overseen by the Department of State Bureau of Global Health Security and Diplomacy and $1.3 billion for multilateral organizations ($1.25 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria as the first installment of a $4.6 billion pledge for the 2026 to 2028 eighth replenishment period, plus $45 million for UNAIDS).

Over more than two decades of operation across more than 50 partner countries, PEPFAR is credited with saving an estimated 26 million lives, preventing 7.8 million babies from being born with HIV infection through prevention of mother-to-child transmission programs, supporting life-saving antiretroviral therapy for 20.6 million people, providing HIV testing for 83.8 million people annually, caring for 6.6 million orphans and vulnerable children, and training 342,000 healthcare workers. Dividing $130 billion in cumulative federal funding by 26 million lives saved yields a historical program-wide average cost of $5,000 per human life saved. Furthermore, in September 2025 and April 2026, the Department of State and the Global Fund announced an expanded commitment to deploy long-acting injectable pre-exposure prophylaxis (PrEP, such as lenacapavir and cabotegravir) to reach up to 3 million high-risk individuals through 2028, even as broader foreign aid reorganizations described in KFF’s PEPFAR status review seek to transition routine clinic financing to host-country health ministries over time.

The President’s Malaria Initiative (PMI) and GiveWell Empirical Benchmarks

Comparable life-saving efficiency is documented in the United States President’s Malaria Initiative (PMI), launched in 2005 and operating across 30 high-burden countries in sub-Saharan Africa and Southeast Asia that account for nearly 90% of global malaria mortality. According to a September 22, 2026 KFF policy review of PMI and the World Health Organization Global Malaria Programme strategy, malaria caused 282 million clinical cases and 610,000 deaths worldwide in 2024, with the vast majority of fatalities occurring among children under five years of age in sub-Saharan Africa. Funded at approximately $805 million annually in bilateral appropriations (within roughly $1.0 billion in total United States bilateral malaria funding and $1.25 billion to $1.65 billion in annual Global Fund contributions, where 29% of Global Fund grants target malaria), PMI has distributed hundreds of millions of insecticide-treated bed nets, artemisinin-based combination therapy treatments, rapid diagnostic tests, indoor residual spraying campaigns, and seasonal malaria chemoprevention courses, helping save 11.7 million lives and prevent 2.1 billion malaria cases across partner nations since 2005.

Independent charity evaluator GiveWell provides granular, step-by-step econometric verification of the cost to save a life through malaria control in its impact estimation methodology and its August 2026 analysis of a $276 million malaria net grant in the Democratic Republic of the Congo. Examining a representative $6.4 million grant to Malaria Consortium for Seasonal Malaria Chemoprevention (SMC) in Nigeria, GiveWell documents that delivering one monthly course of preventive antimalarial medicine (sulfadoxine-pyrimethamine plus amodiaquine) to a child under age five costs approximately $1.37. Across a four-month to five-month high-transmission rainy season (averaging 4.4 monthly cycles, or roughly $6.03 per protected child), a $3,000 expenditure funds 2,189 monthly treatment cycles, fully protecting 498 children under age five. Based on baseline Nigerian child malaria mortality rates (where 4.1 children in that protected and surrounding cohort would otherwise die of malaria annually, with 70%, or 2.9 deaths, occurring during the high-transmission season) and randomized controlled trials showing SMC reduces malaria mortality by 46% (averting 1.3 deaths before crowd-out adjustments, and 1.0 net child death averted after accounting for fungibility with other global donors), GiveWell establishes an empirical cost of $3,000 to $5,500 per human life saved across its top-rated malaria, vitamin A supplementation, and childhood immunization charities.

In his influential book Doing Good Better: How Effective Altruism Can Help You Make a Difference, philosopher William MacAskill highlights this thousand-fold multiplier between high-income domestic expenditures and global health interventions, a global health convergence also documented by physician and statistician Hans Rosling in Factfulness: Ten Reasons We’re Wrong About the World–and Why Things Are Better Than You Think. When evaluating how many lives a reallocated federal agency budget could save, whether Congress directs the money to domestic agencies or international disease eradication programs changes the resulting number of lives saved from tens of thousands to several million per year.

NASA’s Fiscal Year 2026 Budget Architecture and Space-Enabled Mortality Reductions

To evaluate the hypothetical reallocation of all of NASA’s budget to government-funded life-saving programs, an objective analysis must establish NASA’s exact enacted budget as of October 28, 2026, examine how those billions are distributed across exploration, science, operations, and aeronautics, and account for the terrestrial human lives that NASA’s programs already protect.

Enacted Fiscal Year 2026 Appropriations and the $24.4 Billion Topline

NASA’s fiscal posture in 2026 reflects one of the most consequential budget battles in modern American space policy. After operating throughout fiscal year 2024 on $24.875 billion and throughout fiscal year 2025 under a full-year continuing resolution at approximately $24.8 billion (below the agency’s fiscal year 2025 budget request of $25.4 billion), NASA confronted an aggressive austerity proposal in the White House fiscal year 2026 budget request. That request proposed slashing NASA’s discretionary budget by roughly 24% to $18.8 billion, seeking to cancel dozens of science missions and halve the Science Mission Directorate so that human lunar and Mars exploration could be prioritized within a smaller agency topline.

As documented in New Space Economy‘s comprehensive March 30, 2026 analysis of the Planetary Society’s FY 2026 budget guide, Congress decisively rejected the proposed $18.8 billion contraction following an advocacy mobilization detailed by The Planetary Society in which citizens and scientists sent more than 100,000 messages to lawmakers. In the enacted fiscal year 2026 Commerce, Justice, Science, and Related Agencies appropriations law, Congress set NASA’s regular annual discretionary budget at $24.4 billion. Additionally, a separate budget reconciliation law enacted outside the annual discretionary appropriations cap provided $10.0 billion for NASA over six years, directed primarily toward human spaceflight and Artemis infrastructure. When the fiscal year 2026 share of that multi-year reconciliation package is added to the $24.4 billion discretionary appropriation, NASA’s total effective fiscal year 2026 resource base equals approximately $27.53 billion. Even after enactment, executive execution controls remained contentious: in February 2026, NASA temporarily paused new spending on 17 science initiatives while awaiting Office of Management and Budget apportionment guidance, and on April 3, 2026, New Space Economy‘s review of NASA’s proposed FY 2027 budget revealed that the administration again proposed a 23% reduction ($5.6 billion below the 2026 enacted level), seeking to raise Exploration to $8.5 billion while cutting Science from $7.25 billion to $3.9 billion, Space Technology from $921 million to $624 million, Aeronautics from $935 million to $610 million, Safety, Security, and Mission Services from $3.0 billion to under $2.0 billion, and zeroing out the $143 million STEM Engagement account.

Thus, as of October 28, 2026, the authoritative baseline for NASA’s annual budget is the $24.4 billion enacted fiscal year 2026 discretionary budget (with $27.53 billion serving as the upper-bound total resource base including reconciliation funds). Across the enacted $24.4 billion discretionary budget, funding is allocated across seven major accounts:

• Deep Space Exploration Systems ($7.78 billion): Funds the Artemis lunar exploration campaign, including the Space Launch System (SLS) rocket, the Orion crew capsule, Exploration Ground Systems (including Mobile Launcher 2), and commercial Human Landing System contracts. As detailed in New Space Economy‘s April 2026 feature on whether the $93 billion Artemis program is worth its cost and its companion review of NASA Office of Inspector General audit reports, cumulative Artemis spending exceeded $93 billion through fiscal year 2025 (and surpassed $100 billion by spring 2026), with each expendable SLS and Orion launch costing $4.1 billion to $4.2 billion to operate. On April 1, 2026, Artemis II launched four astronauts around the Moon to a record distance of 252,021 statute miles from Earth, with the first crewed lunar south pole landing restructured for Artemis IV in early 2028.
• Science Mission Directorate ($7.25 billion): Funds Earth Science ($2.15 billion in enacted fiscal year 2026 appropriations), Planetary Science (including $500 million for the Dragonfly nuclear-powered rotorcraft to Saturn’s moon Titan), Astrophysics ($1.60 billion, including $300 million to complete the Nancy Grace Roman Space Telescope and $150 million to ramp up the Habitable Worlds Observatory), Heliophysics (space weather monitoring), and Planetary Defense ($300 million for the Near-Earth Object Surveyor infrared space telescope).
• Space Operations ($4.22 billion): Funds operations, crew rotation, cargo resupply, and research aboard the International Space Station (ISS), space communications and navigation networks, and commercial low Earth orbit platform transitions.
• Safety, Security, and Mission Services ($3.00 billion): Funds institutional operations, engineering and safety oversight, environmental remediation, and laboratory maintenance across NASA’s 10 field centers.
• Aeronautics Research Mission Directorate ($935 million): Funds aviation safety, air traffic management modernization, low-emission aircraft propulsion, and hypersonic and supersonic flight research.
• Space Technology Mission Directorate ($921 million): Funds early-stage and maturation-stage space technologies, commercial lunar payload technologies, nuclear thermal and solar electric propulsion, and advanced materials.
• STEM Engagement and Inspector General ($294 million combined, including $143 million for STEM Engagement): Funds university fellowships, Minority University Research and Education Project grants, National Space Grant College and Fellowship programs, and independent audit oversight.

The table below details NASA’s enacted fiscal year 2026 discretionary budget accounts alongside their direct terrestrial health, safety, and survival functions.

Countervailing Risks: How NASA’s Budget Already Saves Lives on Earth

Under OMB Circular A-4, any valid benefit-cost analysis of defunding an existing government agency must evaluate countervailing risks, defined as the mortality and morbidity hazards created when existing safety, scientific, and early-warning capabilities are removed. Treating NASA’s $24.4 billion budget as a zero-mortality-benefit luxury ignores four concrete mechanisms through which civil space programs actively preserve human life on Earth.

First, NASA’s $2.15 billion Earth Science Division designs, launches, and calibrates the orbital remote-sensing instruments that underpin global weather forecasting, hurricane rapid-intensification modeling, flood inundation mapping, wildfire detection, agricultural famine prevention, and extreme heat monitoring. As documented in New Space Economy‘s analyses of how space benefits everyday life, the Earth observation market, and space-enabled applications, instruments such as the Moderate Resolution Imaging Spectroradiometer (MODIS) and the Visible Infrared Imaging Radiometer Suite (VIIRS) detect nascent forest fires from orbit and track hazardous PM2.5 wildfire smoke plumes across North America, allowing asthma and cardiac patients to shelter indoors. Synthetic aperture radar missions such as the NASA-ISRO Synthetic Aperture Radar (NISAR) and radar altimetry satellites penetrate dense hurricane cloud cover to measure storm surge, river gauge overflow, and levee subsidence. Thermal infrared radiometers map urban heat islands where combined heat and humidity approach lethal wet-bulb thresholds above 95 degrees Fahrenheit (35 degrees Celsius), a growing public health hazard analyzed in New Space Economy‘s reports on extreme heat survival limits and space solutions for climate change. Without NASA’s sensor research and joint satellite development with the National Oceanic and Atmospheric Administration (NOAA), multi-day hurricane evacuation lead times and famine early-warning systems (such as the Famine Early Warning Systems Network, which combines NASA vegetation and soil-moisture satellite indices with agricultural market data) would degrade, costing thousands of lives annually during severe weather and drought emergencies.

Second, NASA’s $935 million Aeronautics Research Mission Directorate serves as the foundational research-and-development arm for United States civil aviation safety. Commercial airline travel in the United States is the safest mode of human transportation in history largely because NASA wind tunnels, flight simulators, and test aircraft developed airborne Doppler wind-shear radar (preventing fatal microburst crashes during takeoff and landing), aircraft wing ice-accretion physics models, digital fly-by-wire fault-tolerant computers, hydroplaning-resistant grooved airport runways, composite fuselage damage-tolerance standards, and the confidential Aviation Safety Reporting System (ASRS) operated by NASA to identify near-misses before fatal airline accidents occur.

Third, NASA’s biomedical research aboard the International Space Station and its formal technology transfer pipelines have generated thousands of clinical innovations on Earth. As examined in New Space Economy‘s review of the NASA Spinoff Program and its study of pharmaceuticals on the space station, NASA has documented more than 2,000 commercialized spinoff technologies since 1976. Life-saving medical spinoffs include the MicroMed DeBakey Ventricular Assist Device (developed using NASA Ames supercomputer fluid-dynamics modeling of Space Shuttle main engine fuel pumps to pump blood without shearing red blood cells), digital charge-coupled device image-processing software from the Hubble Space Telescope that enabled low-dose stereotactic needle breast biopsies, programmable bidirectional cardiac pacemakers, portable ultrasound diagnostic protocols created to examine astronauts in orbit and now deployed in rural ambulances and developing-world maternity wards, and microgravity protein-crystallization experiments aboard the ISS that have accelerated monoclonal antibody drug formulation for oncology and muscular dystrophy. Former NASA Deputy Administrator Lori Garver details in Escaping Gravity: My Quest to Transform NASA and Launch a New Space Age, and aerospace engineer Robert Zubrin explores in The Case for Space: How the Revolution in Spaceflight Opens Up a Future of Limitless Possibility, how transitioning low Earth orbit transport and lunar cargo to fixed-price commercial partnerships can free up scientific capital for high-value orbital research and planetary protection.

Fourth, NASA’s Planetary Defense Coordination Office and its $300 million fiscal year 2026 appropriation for the NEO Surveyor space telescope protect humanity against low-probability, high-fatality asteroid and comet impacts. As documented in New Space Economy‘s guides to planetary defense technologies and the history of planetary defense, as well as public opinion analyses of NASA’s budget priorities, a 20-meter meteor airburst over Chelyabinsk, Russia, in February 2013 injured more than 1,000 people, the 1908 Tunguska impact flattened 2,000 square kilometers of Siberian forest, and an impact by a 140-meter city-killer or one-kilometer civilization-scale near-Earth asteroid could kill millions to billions of human beings. Because NASA’s Double Asteroid Redirection Test (DART) mission successfully demonstrated kinetic asteroid deflection in September 2022, completing the NEO Surveyor infrared telescope to catalog 90% of potentially hazardous asteroids larger than 140 meters provides irreplaceable planetary insurance.

Quantitative Reallocation Scenarios: How Many Lives Could NASA’s Budget Save?

Synthesizing the verified data across federal VSL benchmarks ($13.6 million to $14.2 million), United States mortality statistics (3,072,666 final deaths in 2024 and 3,094,593 provisional deaths in 2025), federal program cost-effectiveness ratios ($3,000 to $14.2 million per life saved), and NASA’s enacted fiscal year 2026 budget ($24.4 billion discretionary topline, or $27.53 billion including reconciliation funds) enables a transparent quantitative calculation of how many human lives could potentially be saved if 100% of NASA’s budget were reallocated to life-saving programs.

Methodological Principles: Marginal Diminishing Returns and Appropriations Firewalls

To ensure economic rigor, two structural principles must govern the calculation:

1. Average Cost Versus Marginal Cost-Effectiveness: Dividing $24.4 billion by the lowest historical average cost per life saved of a small program produces an unrealistic theoretical ceiling because it ignores diminishing marginal returns and population saturation. For example, although the CDC Tips From Former Smokers media campaign averts premature smoking deaths for under $4,000 per life saved on an annual budget of $240 million, pouring $24.4 billion (a 100-fold increase) exclusively into anti-smoking television ads would rapidly saturate media channels without proportionate cessation gains. Similarly, although community naloxone kits save a life for $3,000 to $15,000 among high-risk fentanyl users, total United States drug overdose deaths were 79,384 in 2024; no amount of naloxone funding can save more than 79,384 overdose victims per year in the United States. Therefore, realistic modeling must diversify the $24.4 billion across multiple high-burden causes of death and apply upward marginal-cost adjustments to account for rural outreach costs, clinical staffing bottlenecks, and diminishing returns.
2. Legislative Appropriations Separation: As noted in New Space Economy‘s analysis of the Artemis program, federal spending is partitioned across 12 distinct Congressional Appropriations Subcommittees. NASA sits within the Commerce, Justice, Science, and Related Agencies (CJS) bill, whereas the CDC, SAMHSA, NIH, and HRSA sit within the Labor, Health and Human Services, Education, and Related Agencies bill, DOT sits within the Transportation and Housing bill, and PEPFAR and PMI sit within the State and Foreign Operations bill. The scenarios below model an explicit statutory reallocation in which Congress transfers $24.4 billion (or $27.53 billion) in annual budget authority from NASA to designated health and safety accounts.

Scenario One: Federal VSL Break-Even Parity ($14.1 Million to $14.2 Million per Life)

In the first scenario, suppose NASA’s entire enacted fiscal year 2026 budget is reallocated to marginal federal environmental, occupational, or transportation safety mandates whose compliance cost per prevented fatality equals the official federal VSL break-even threshold:

• At the DOT 2025/2026 VSL Benchmark ($14.2 million per statistical life): Reallocating the $24.4 billion discretionary budget saves 1,718 statistical lives per year. Reallocating the $27.53 billion total resource base saves 1,939 statistical lives per year.
• At the HHS ASPE 2026 VSL Benchmark ($14.1 million per statistical life): Reallocating $24.4 billion saves 1,730 statistical lives per year (and $27.53 billion saves 1,952 statistical lives per year).
• At the EPA Adjusted VSL Benchmark (approximately $13.6 million per statistical life): Reallocating $24.4 billion saves 1,794 statistical lives per year (and $27.53 billion saves 2,024 statistical lives per year).
• At the HHS ASPE 2026 VSLY Benchmark ($607,402 per discounted life-year): Reallocating $24.4 billion purchases 40,171 discounted statistical life-years per year (or 45,324 discounted life-years using $27.53 billion), equivalent to saving 2,678 to 4,017 lives per year when each prevented premature death preserves 10 to 15 discounted years of life.

Scenario One establishes the conservative domestic floor: even if the reallocated budget were spent on the least cost-effective regulations that still pass a federal benefit-cost test, it would save roughly 1,718 to 2,024 American lives annually.

Scenario Two: United States Highway Engineering and Trauma Infrastructure ($1.6 Million to $3.0 Million Marginal Cost)

In the second scenario, suppose NASA’s $24.4 billion discretionary budget is transferred to the Department of Transportation to expand the Federal Highway Administration’s Highway Safety Improvement Program (currently $3.1 billion to $3.3 billion annually) nearly ninefold, funding nationwide installation of median cable barriers, rural centerline and shoulder rumble strips, modern roundabout conversions at high-crash intersections, urban pedestrian hybrid beacons and road diets, automated speed cameras in school and work zones, and rural Level I trauma air-ambulance networks.

• Linear Average-Cost Ceiling ($500,000 to $1.0 million per life saved): Using the FHWA Texas HSIP optimization benchmark ($1.0 million per life saved) and rural rumble-strip and cable-barrier averages ($500,000 per life saved), $24.4 billion would theoretically equal 24,400 to 48,800 lives saved per year.
• Realistic Marginal-Cost Estimate ($1.6 million to $3.0 million per life saved): Because total United States motor vehicle traffic fatalities are approximately 40,000 per year across all roadways, and a substantial fraction of fatal crashes involve severe intoxication, extreme speeding, or unbuckled occupants that roadway engineering alone cannot eliminate, scaling HSIP by $24.4 billion per year encounters diminishing marginal returns as states move from high-crash corridors to lower-density rural roads. At a realistic marginal cost of $1.6 million to $3.0 million per prevented traffic and trauma fatality, reallocating $24.4 billion saves 8,133 to 15,250 American lives per year (or 9,177 to 17,206 lives per year using the $27.53 billion total resource base), cutting United States highway mortality by 20% to 38%.

Scenario Three: Diversified United States Domestic Public Health Portfolio ($233,000 to $407,000 Blended Marginal Cost)

In the third scenario, suppose Congress reallocates NASA’s $24.4 billion discretionary budget across a diversified five-pillar domestic public health and clinical prevention portfolio engineered to attack the leading modifiable causes of death in the United States (heart disease at 683,491 deaths, cancer at 619,876, unintentional overdose and injury deaths at 197,449, stroke at 166,852, chronic lower respiratory diseases at 145,643, diabetes at 94,445, kidney disease at 55,081, liver cirrhosis at 52,274, suicide at 48,824, and infant mortality at 20,050) without saturating any single clinical delivery channel:

1. Pillar One: $6.0 Billion Annual Expansion for SAMHSA and HRSA Opioid Overdose Reversal and Addiction Pharmacotherapy: Quadruples current State and Tribal Opioid Response funding ($1.5 billion baseline) to saturate high-risk communities, emergency rooms, jails, shelters, and rural pharmacies with free over-the-counter intranasal naloxone and nalmefene, mobile buprenorphine and methadone treatment vans, fentanyl and xylazine test strips, and contingency management for methamphetamine and cocaine addiction. Allowing for diminishing marginal returns that raise the marginal cost per prevented overdose death from the $3,000–$35,000 baseline to $240,000 to $400,000 per incremental life saved, this $6.0 billion allocation saves 15,000 to 25,000 American lives per year (reducing the remaining 79,384 annual drug overdose deaths by 19% to 31%).
2. Pillar Two: $6.4 Billion Annual Expansion for CDC and HRSA Cardiovascular, Hypertension, Diabetes, and Stroke Control: Funds universal zero-copay generic antihypertensive medications, statins, SGLT2 inhibitors, and GLP-1 cardiometabolic therapies at Federally Qualified Health Centers and rural clinics, paired with community pharmacist blood-pressure titration, automated external defibrillator placement, and rural tele-stroke mechanical thrombectomy networks targeting the 850,343 combined heart disease and stroke deaths and 149,526 diabetes and kidney deaths. At a realistic scaled marginal cost of $180,000 to $320,000 per premature cardiometabolic death prevented, this $6.4 billion allocation saves 20,000 to 35,556 American lives per year.
3. Pillar Three: $6.0 Billion Annual Expansion for CDC Universal Uninsured Cancer Screening, Hepatitis C Cure, and Oncology Navigation: Expands the CDC National Breast and Cervical Cancer Early Detection Program and Colorectal Cancer Control Program ($250 million baseline) 24-fold to provide free mammograms, Pap and HPV tests, colonoscopies, fecal immunochemical tests, low-dose CT lung cancer screening for smokers, curative direct-acting antiviral treatment for chronic hepatitis C (preventing liver cancer and cirrhosis), and guaranteed diagnostic and surgical navigation for all uninsured and underinsured adults. At a realistic scaled marginal cost of $300,000 to $500,000 per cancer or hepatic death prevented, this $6.0 billion allocation saves 12,000 to 20,000 American lives per year.
4. Pillar Four: $3.0 Billion Annual Expansion for CDC Tobacco Control, VFC Childhood Catch-Up Immunization, and COPD/Asthma Filtration: Expands the CDC National Tobacco Control Program ($240 million baseline) and VFC immunization outreach to provide free combination nicotine replacement therapy, varenicline, intensive quitline counseling, high-efficiency particulate air filtration for low-income COPD and asthma patients, and mobile pediatric vaccination clinics closing the 61%-versus-75% poverty immunization gap. At a realistic marginal cost of $200,000 to $375,000 per respiratory, tobacco, or infectious death averted, this $3.0 billion allocation saves 8,000 to 15,000 American lives per year.
5. Pillar Five: $3.0 Billion Annual Expansion for the 988 Suicide and Crisis Lifeline, Mobile Crisis Outreach, and Maternal-Infant Home Visiting: Expands federal 988 crisis infrastructure ($500 million baseline) sixfold to deploy 24/7 two-person behavioral mobile crisis teams in every county, short-term psychiatric stabilization beds, emergency department lethal-means counseling, and Nurse-Family Partnership prenatal and neonatal safe-sleep home visiting targeting the 48,824 suicide deaths and 20,050 infant deaths. At a realistic marginal cost of $333,000 to $600,000 per suicide or infant death prevented, this $3.0 billion allocation saves 5,000 to 9,000 American lives per year.

Summing across all five domestic pillars, reallocating NASA’s $24.4 billion discretionary budget into an evidence-based United States public health portfolio saves 60,000 to 104,556 American lives per year (at a blended marginal cost of $233,368 to $406,667 per domestic life saved). If NASA’s full $27.53 billion resource base is deployed across the same five pillars, the portfolio saves 67,697 to 117,969 American lives per year. Valued at the 2026 HHS ASPE VSL of $14.1 million per statistical life, saving 60,000 to 104,556 American lives annually generates $846.0 billion to $1.474 trillion in annual monetized mortality benefits, a 34-to-1 to 60-to-1 benefit-cost return on the $24.4 billion expenditure.

Scenario Four: Global Health Reallocation to PEPFAR, PMI, and Child Survival ($7,500 to $12,000 Scaled Marginal Cost)

In the fourth scenario, suppose Congress reallocates NASA’s $24.4 billion discretionary budget (or $27.53 billion total resource base) to United States bilateral and multilateral global health programs (PEPFAR, the President’s Malaria Initiative, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Gavi childhood immunization) to maximize the total number of human lives saved worldwide regardless of nationality:

• Linear Average-Cost Ceiling ($3,000 to $5,000 per life saved): Dividing $24.4 billion by GiveWell’s $3,000 to $5,000 empirical cost per life saved for seasonal malaria chemoprevention and insecticide-treated nets (and PEPFAR’s $5,000 historical average across 26 million lives) yields a theoretical linear ceiling of 4,880,000 to 8,133,333 human lives saved per year (or 5,506,000 to 9,176,667 lives per year using $27.53 billion).
• Realistic Absorptive-Capacity and Disease-Burden Estimate ($7,500 to $12,000 per life saved): Because global malaria deaths total 610,000 per year and global HIV/AIDS deaths total 630,000 per year, deploying $24.4 billion annually requires expanding beyond malaria chemoprevention and HIV antiretrovirals to fund global tuberculosis treatment (1.25 million annual deaths), rotavirus and pneumococcal childhood vaccination, oral rehydration and zinc for pediatric diarrheal disease, maternal emergency obstetrics, and rural clinic cold-chain and nursing infrastructure across 60 low- and middle-income nations. Applying a realistic large-scale marginal cost of $7,500 to $12,000 per life saved to account for health-system capacity expansion and diminishing returns, reallocating NASA’s $24.4 billion discretionary budget saves 2,033,333 to 3,253,333 human lives per year worldwide (and reallocating the $27.53 billion total resource base saves 2,294,167 to 3,670,667 human lives per year worldwide). Even valued at the conservative 2024 WHO global average VSL of 3.76 million international dollars per statistical life, saving 2.03 million to 3.25 million lives annually generates 7.64 trillion to 12.23 trillion international dollars in global mortality reduction value every year.

Scenario Five: Countervailing Risk-Adjusted Partial Reallocation ($21.01 Billion Shifted)

In the fifth and most analytically complete scenario, policymakers account for the countervailing mortality risks of abolishing NASA’s Earth-protecting divisions. As established in the preceding section, three accounts within NASA’s enacted fiscal year 2026 budget directly prevent premature deaths on Earth: the $2.15 billion Earth Science Division (hurricane, flood, wildfire smoke, drought, and extreme wet-bulb heat forecasting), the $935 million Aeronautics Research Directorate (commercial aviation collision, wind-shear, and icing safety), and the $300 million NEO Surveyor Planetary Defense program (catastrophic asteroid impact detection). Together, those three protective programs cost $3.385 billion (13.9% of NASA’s $24.4 billion discretionary budget).

If Congress preserves that $3.385 billion Earth-safety, climate, aviation, and planetary defense core intact (or transfers those exact satellites and research centers intact to NOAA and the FAA) and reallocates only the remaining $21.015 billion discretionary balance (86.1% of NASA’s budget, comprising Deep Space Exploration, ISS Space Operations, Space Technology, STEM Engagement, and associated Mission Services overhead), society incurs zero countervailing weather, climate, aviation, or asteroid mortality losses while saving:

• 1,480 to 1,490 domestic statistical lives per year under Scenario One (VSL parity at $14.1 million to $14.2 million);
• 7,005 to 13,134 American lives per year under Scenario Two (highway engineering and trauma infrastructure);
• 51,676 to 90,050 American lives per year under Scenario Three (diversified domestic public health portfolio); or
• 1,751,250 to 2,802,000 human lives per year worldwide under Scenario Four (global infectious disease and maternal-child survival portfolio).

The table below presents the complete comparative results across all five quantitative reallocation scenarios for NASA’s enacted fiscal year 2026 discretionary budget of $24.4 billion.

Summary

Evaluating the monetary value of a human life, the epidemiology of United States mortality, the cost-effectiveness of government health and safety interventions, and the opportunity cost of NASA’s budget reveals the power and the limits of benefit-cost reasoning in public policy. In 2026, United States regulatory agencies value the prevention of a single statistical fatality at $13.6 million to $14.2 million, led by the Department of Transportation’s $14.2 million benchmark (2025 base year) and the Department of Health and Human Services ASPE’s $14.1 million estimate for 2026 ($607,402 per statistical life-year and $722,068 per quality-adjusted life-year), alongside the Consumer Product Safety Commission’s doubled child benchmark of $26.0 million in 2023 dollars and the World Health Organization’s global average benchmark of 3.76 million international dollars. Derived from hedonic wage-risk regressions and stated-preference studies, these figures measure collective willingness to pay for micro-risk reductions rather than the intrinsic dignity of an identified human being.

National Vital Statistics System records published by the CDC in January 2026 and provisional 2025 mortality analyses published by HHS ASPE in October 2026 demonstrate that 3,072,666 Americans died in 2024 (an age-adjusted rate of 722.1 per 100,000, improving to a record-low provisional rate of 689.2 in 2025, or 689.8 on a harmonized Census Vintage 2025 basis), with life expectancy at birth rising to 79.0 years. Ten leading causes accounted for 70.9% of all 2024 deaths: heart disease (683,491), cancer (619,876), unintentional injuries (197,449), stroke (166,852), chronic lower respiratory diseases (145,643), Alzheimer disease (116,022), diabetes (94,445), kidney disease (55,081), chronic liver disease and cirrhosis (52,274), and suicide (48,824, replacing COVID-19 in the 10th position). A 26.2% drop in age-adjusted drug overdose mortality in 2024 (from 105,007 to 79,384 deaths, driven by a 35.6% plunge in synthetic opioid fatalities and followed by another 20.7% synthetic opioid decline in 2025) proves that targeted public health funding and supply interdiction can rapidly save tens of thousands of lives.

When NASA’s enacted fiscal year 2026 discretionary budget of $24.4 billion ($27.53 billion including reconciliation funds) is modeled across empirical cost-per-life-saved benchmarks, the projected mortality impact depends entirely on which programs receive the funds. Reallocating $24.4 billion to break-even regulatory mandates costing $14.1 million to $14.2 million per life saves 1,718 to 1,730 lives per year. Reallocating the funds to highway safety engineering saves 8,133 to 15,250 American lives per year. Deploying $24.4 billion across a diversified domestic public health portfolio (naloxone and addiction pharmacotherapy, hypertension and stroke control, uninsured cancer screening, tobacco cessation, and the 988 Suicide and Crisis Lifeline) realistically saves 60,000 to 104,556 American lives every year, generating $846 billion to $1.47 trillion in monetized VSL benefits. Deploying the same $24.4 billion internationally through PEPFAR, the President’s Malaria Initiative, and global child immunization at a scaled marginal cost of $7,500 to $12,000 per life saves 2.03 million to 3.25 million human lives per year worldwide. Yet because NASA’s $2.15 billion Earth Science Division, $935 million Aeronautics Directorate, and $300 million Planetary Defense program actively save lives through hurricane warnings, wildfire tracking, aviation safety, and asteroid detection, and because NASA represents less than 0.4% of total federal spending, the evidence demonstrates that expanding high-yield domestic and global health programs does not require dismantling the scientific and orbital infrastructure that protects Earth.

Appendix: Useful Books Available on Amazon

• What Money Can’t Buy: The Moral Limits of Markets
• Doing Good Better: How Effective Altruism Can Help You Make a Difference
• Factfulness: Ten Reasons We’re Wrong About the World–and Why Things Are Better Than You Think
• Escaping Gravity: My Quest to Transform NASA and Launch a New Space Age
• The Case for Space: How the Revolution in Spaceflight Opens Up a Future of Limitless Possibility
• Taming Cancer: 21st Century Biology and the Future of Cancer Medicine

Appendix: Top Questions Answered in This Article

What Is the Official Monetary Value of a Statistical Human Life in the United States in 2026?

In 2026, primary United States federal regulatory agencies value a statistical human life between $13.6 million and $14.2 million. Specifically, the Department of Transportation uses a benchmark of $14.2 million in 2025 base dollars, and the Department of Health and Human Services uses a central estimate of $14.1 million for 2026. These figures measure aggregate willingness to pay for small mortality risk reductions rather than the intrinsic moral worth of an individual person.

How Does the Consumer Product Safety Commission Value Fatal Risk Reductions for Children?

Under final guidance published in April 2024, the Consumer Product Safety Commission sets the Value per Statistical Life for children at twice the adult benchmark. In 2023 base dollars and real income levels, the commission applies $26.0 million for a child compared with $13.0 million for an adult. Empirical revealed-preference and stated-preference studies confirm that parents and society exhibit a substantially higher willingness to pay to protect children from fatal hazards.

What Were the Top Three Leading Causes of Death in the United States in 2024?

According to final mortality data published by the CDC National Center for Health Statistics in January 2026, the top three leading causes of death in 2024 were heart disease (683,491 deaths), cancer (619,876 deaths), and unintentional injuries (197,449 deaths). Together, those three categories accounted for 1,500,816 deaths, or 48.8% of the 3,072,666 total resident deaths registered in the United States during 2024. Age-adjusted death rates declined across all 10 leading causes between 2023 and 2024.

Why Did United States Life Expectancy Increase and the Age-Adjusted Death Rate Reach a Record Low?

United States life expectancy at birth increased by 0.6 year to 79.0 years in 2024, and the provisional age-adjusted death rate reached a record low of 689.2 per 100,000 in 2025. Analyses by the CDC and HHS ASPE demonstrate that plummeting unintentional drug overdose deaths, declining COVID-19 mortality, and steady improvements in cardiovascular and cancer mortality drove the gains. Synthetic opioid overdose deaths fell by 35.6% in 2024 and dropped another 20.7% in 2025.

Which Domestic Government Programs Save Human Lives at the Lowest Cost per Death Averted?

Routine childhood immunization through the CDC Vaccines for Children program is the most cost-effective domestic intervention, having prevented 1.13 million deaths and saved $2.7 trillion in societal costs across the 1994 through 2023 birth cohorts. Among discretionary grant programs, the CDC National Tobacco Control Program’s media campaigns avert premature smoking deaths for under $4,000 per life saved, and SAMHSA community naloxone distribution grants reverse fatal opioid overdoses for roughly $3,000 to $15,000 per life saved.

How Much Does It Cost United States Global Health Programs to Save a Life Internationally?

United States bilateral and multilateral global health programs save lives at a small fraction of domestic regulatory costs because baseline infectious disease mortality is high and proven treatments are inexpensive. Since 2003, the President’s Emergency Plan for AIDS Relief (PEPFAR) has saved 26 million lives across $130 billion in cumulative appropriations, averaging $5,000 per life saved. Independent charity evaluator GiveWell similarly estimates that seasonal malaria chemoprevention and insecticide-treated nets save a child’s life for $3,000 to $5,000.

What Is NASA’s Enacted Budget for Fiscal Year 2026?

Congress enacted a fiscal year 2026 regular discretionary budget of $24.4 billion for NASA, rejecting a White House request to cut the agency’s funding by 24% to $18.8 billion. When combined with the annual installment of a separate six-year, $10.0 billion reconciliation package focused on human exploration, NASA’s total effective fiscal year 2026 resource base equals approximately $27.53 billion. Deep Space Exploration ($7.78 billion) and the Science Mission Directorate ($7.25 billion) represent the two largest accounts.

How Many American Lives Could Be Saved Annually if NASA’s Budget Funded Domestic Public Health?

If NASA’s entire $24.4 billion enacted fiscal year 2026 discretionary budget were reallocated to a diversified domestic public health portfolio, economic modeling indicates it could save between 60,000 and 104,556 American lives per year. That portfolio would distribute funds across community naloxone and addiction treatment ($6.0 billion), hypertension and stroke control ($6.4 billion), uninsured cancer screening ($6.0 billion), tobacco cessation ($3.0 billion), and the 988 Suicide and Crisis Lifeline ($3.0 billion).

How Many Lives Could NASA’s Budget Save Globally if Directed to International Disease Relief?

If NASA’s $24.4 billion discretionary budget were redirected to international infectious disease and child survival programs such as PEPFAR, the President’s Malaria Initiative, and Gavi childhood vaccination, it could save between 2.03 million and 3.25 million human lives per year worldwide. Although linear division at $3,000 to $5,000 per life yields 4.88 million to 8.13 million lives, realistic modeling adjusts the marginal cost to $7,500 to $12,000 per life to account for health-system absorptive capacity.

Does NASA’s Existing Budget Currently Save Human Lives on Earth?

Yes, several divisions within NASA’s budget directly prevent premature mortality on Earth, creating countervailing risks if defunded. NASA’s $2.15 billion Earth Science Division builds and operates meteorological and climate satellites that provide early evacuation warnings for hurricanes, floods, extreme heat waves, and wildfires. Additionally, NASA’s $935 million Aeronautics Research Directorate develops collision-avoidance, wind-shear, and icing safety systems for commercial aviation, and its $300 million NEO Surveyor mission protects Earth from catastrophic asteroid impacts.

Appendix: Glossary of Key Terms

Value of a Statistical Life

An economic metric representing the aggregate dollar amount that a large group of individuals is willing to pay for small reductions in premature mortality risk such that one fewer death is expected across the group over a specified period, used by government agencies to evaluate safety regulations.

Hedonic Wage-Risk Model

An econometric regression method that estimates the implicit monetary value workers place on mortality and injury risks by measuring the compensating wage premium paid to employees in occupations with higher fatal accident rates after controlling for worker education, experience, and industry characteristics.

Regulatory Impact Analysis

A formal quantitative evaluation required under Presidential Executive Order 12866 and Office of Management and Budget Circular A-4 for major federal rulemakings, comparing the monetized societal benefits of health, safety, and environmental risk reductions against the economic compliance costs imposed on businesses and consumers.

Value of a Statistical Life Year

A longevity valuation measure derived by dividing the Value of a Statistical Life by the discounted remaining life expectancy of a representative adult, used by health economists to evaluate medical and public health interventions that extend survival by a specific number of years.

Quality-Adjusted Life Year

A generic measure of disease burden that combines the duration of human survival with a health-related quality-of-life utility weight ranging from zero for death to 1.0 for perfect health, enabling analysts to compare clinical interventions that alleviate chronic morbidity as well as mortality.

Age-Adjusted Death Rate

A standardized mortality metric that applies age-specific death rates from a study population to a fixed standard population age distribution, allowing demographers and epidemiologists to compare mortality risk across different years or demographic groups without distortion from population aging.

Synthetic Opioids Other Than Methadone

A pharmacological category coded as T40.4 in the International Classification of Diseases that includes illicitly manufactured fentanyl, fentanyl analogs, and tramadol, which drove the surge in United States drug overdose deaths through 2022 and the subsequent historic overdose mortality decline during 2024 and 2025.

Vaccines for Children Program

A federally entitlement-funded public health program administered by the Centers for Disease Control and Prevention since October 1994 that provides routine childhood immunizations at no cost to Medicaid-eligible, uninsured, underinsured, and American Indian or Alaska Native children aged 18 and younger.

State Opioid Response Grants

Federal formula and discretionary grants administered by the Substance Abuse and Mental Health Services Administration that provide more than $1.5 billion annually to state and tribal health agencies to distribute naloxone overdose reversal medications and expand access to buprenorphine, methadone, and recovery support services.

Crash Modification Factor

A multiplicative engineering index used by the Federal Highway Administration and state transportation departments to compute the expected percentage reduction in fatal and injury motor vehicle crashes after installing a specific roadway safety countermeasure such as median cable barriers or rumble strips.

Fine Particulate Matter

Microscopic inhalable air pollutant particles measuring 2.5 micrometers or smaller in aerodynamic diameter, emitted by power plants, motor vehicles, industrial processes, and wildfires, which penetrate deep into human lungs and the bloodstream to cause fatal heart attacks, strokes, lung cancer, and respiratory disease.

President’s Emergency Plan for AIDS Relief

The United States government’s flagship global health initiative launched in 2003 to combat the human immunodeficiency virus and acquired immunodeficiency syndrome epidemic, credited with saving 26 million lives worldwide through bilateral treatment programs and contributions to the Global Fund.

Seasonal Malaria Chemoprevention

A highly cost-effective public health intervention recommended by the World Health Organization in which young children in regions with seasonal malaria transmission receive monthly courses of antimalarial medicine during the peak rainy season, preventing roughly 75% of severe malaria episodes and deaths.

Countervailing Risk

An adverse health, safety, or environmental hazard inadvertently created or exacerbated by a policy action or budget reallocation, such as the loss of hurricane evacuation warnings, wildfire tracking, or aviation safety technologies that would occur if Earth observation and aeronautics programs were abolished.

Marginal Cost-Effectiveness

The incremental dollar expenditure required to save one additional human life or gain one additional quality-adjusted life year when an existing program is expanded beyond its current operating scale, reflecting diminishing returns as high-risk populations are saturated and logistical bottlenecks emerge.